Wednesday, November 7, 2001

1:00 pm  Regency Ballroom
Welcome and Introductions
William W. Chin  ATA President
Paul W. Ladenson  ATA Secretary
Wolfgang H. Dillmann  ATA Program Chair, Scientific
Michael M. Kaplan  ATA Program Chair, Clinical

1:15 - 2:00 pm  Regency Ballroom
Keynote Clinical Address
Treatment of Hypothyroidism: What Is Optimal?
Anthony D. Toft, M.D.
Royal Infirmary of Edinburgh, Edinburgh, Scotland
Supported by an educational grant from Abbott Laboratories

2:00 - 3:00 pm  Regency Ballroom
Plenary Session – Topic Highlights
Oral Abstract Presentations
Chairs:  Wolfgang H. Dillmann and Gregory A. Brent

249 2:00 pm  Clinical
RE-DEFINING THE MODERN STANDARD FOR OPEN THYROIDECTOMY
J.H. Yim, S.E. Carty
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

Program Number 1 has been withdrawn

2 2:15 pm  Cell Biology
TSH SERVICES AS A NEGATIVE REGULATOR OF OSTEOBLAST AND OSTEOCLAST DEVELOPMENT AND FUNCTION AS DEMONSTRATED IN THE TSH RECEPTOR KNOCK-OUT MOUSE
R.C. Marians¹, E. Abe¹, X.B. Wu¹, H.C. Blair², M. Zaidi¹, T.F. Davies¹
¹Division of Endocrinology, Diabetes, and Bone Diseases, Mount Sinai Medical Center, New York, New York, and ²Department of Pathology, University of Pittsburgh, Pennsylvania, USA

3 2:30 pm  Thyroid and the Brain
VISUAL PROCESSING DEFICITS ASSOCIATED WITH PERINATAL AND NEONATAL THYROID HORMONE DEFICIENCIES
J. Rovet, G. Mirabella, C. Westall, A. Perrom, K. Perlman
Hospital for Sick Children, Toronto, Ontario, Canada
Wednesday, November 7, 2001
Afternoon Session and Poster Plus – Regency Ballroom

4  2:45 pm  Thyroid Hormone Metabolism
COCHLEAR DEFECTS AND DEAFNESS IN MICE LACKING TYPE II
SELENODEIODINASE
D. Forrest¹, L. Ng¹, M. Kelley², M.J. Schneider³, D.L. St. Germain³, V.A. Galton³
¹Department of Human Genetics, Mount Sinai School of Medicine, New York, New York;
²National Institute of Deafness and Other Communication Disorders, National Institutes of
Health, Rockville, Maryland; and ³Departments of Medicine and Physiology, Dartmouth Medical
College, Lebanon, New Hampshire, USA

3:00 - 4:00 pm Ambassador and Regency Ballrooms
Exhibits, Poster Review, and Coffee Break
Regency Ballroom
Review of Posters:
Program Numbers 5 to 40 (Poster Plus)
Program Numbers 41 to 100
Investigators available to discuss their posters

Poster Plus (Program Numbers 5 to 40):
These posters will be displayed from Wednesday at 3:00 pm through Friday at 1:00 pm

5  Autoimmunity
ESTABLISHMENT OF A NOVEL MURINE MODEL OF GRAVES'
HYPERTHYROIDISM WITH INTRAMUSCULAR INJECTION OF ADENOVIRUS
EXPRESSING THYROTROPIN RECEPTOR
Y. Nagayama, M. Furuyama-Kita, T. Ando, K. Eguchi, M. Niwa
Departments of Pharmacology 1 and Internal Medicine 1, Nagasaki University School of
Medicine, Nagasaki, Japan

6  Autoimmunity
CTLA-4 AT-REPEAT POLYMORPHISM REDuces THE INHIBITORY FUNCTION
OF
CTLA-4 IN GRAVES' DISEASE
M. Takara, T. Kouki, L.J. DeGroot
Thyroid Study Unit, Section of Endocrinology, Department of Medicine, University of Chicago,
Chicago, Illinois, USA

Program Number 7 has been withdrawn

8  Autoimmunity
LACK OF ASSOCIATION BETWEEN THE VITAMIN D RECEPTOR GENE
POLYMORPHISMS AND GRAVES’ DISEASE IN THE UK
Division of Medical Sciences, Department of Medicine, University of Birmingham, Birmingham
Heartlands, and Queen Elizabeth Hospital, Birmingham, United Kingdom
9  Autoimmunity
INTERFERON-γ PRODUCTION IS AN ANTIGEN-SPECIFIC MARKER OF T CELL SENSITIZATION IN TSHR-DNA VACCINATED MICE BUT ITS ABSENCE DOES NOT ENHANCE ANTIBODY LEVELS
P.N. Pichurin, O.A. Pichurina, G.D. Chazenbalk, B. Rapoport, S.M. McLachlan
Autoimmune Disease Unit, Cedars-Sinai Research Institute and UCLA School of Medicine, Los Angeles, California, USA

10  Autoimmunity
THE MHC CLASS II REGION, CTLA-4 GENE AND OPHTHALMOPATHY IN GRAVES' DISEASE
A. Allahabadia, J. Heward, R. Nithiyananthan, S. Gibson, T. Reuser, P. Dodson, J. Franklyn, S. Gough
Division of Medical Sciences, University of Birmingham, Birmingham, United Kingdom

11  Cancer
EFFECTIVE AND NON-TOXIC GENETIC IMMUNOTHERAPY FOR METASTATIC MEDULLARY THYROID CARCINOMA USING ADENOVIRUS-MEDIATED TUMOR-SPECIFIC EXPRESSION OF INTERLEUKIN-12
M. Yamazaki, R. Zhang, L.J. DeGroot
Thyroid Study Unit, Section of Endocrinology, Department of Medicine, University of Chicago, Chicago, Illinois, USA

12  Cancer
DISTINCTIVE EXPRESSION OF STAT3 IN PAPILLARY THYROID CARCINOMA AND A SUBSET OF FOLLICULAR ADENOMAS
Dip. di Patologia Umana & Sezione di Endocrinologia, Dip. Clinico Sperimentale di Medicina e Farmacologia, University of Messina, Messina, Italy

Program Number 13 will be displayed as a regular poster in the #50 slot

50  Cancer
TPO MEDIATES RADIOIODINE ORGANIFICATION WITH AND WITHOUT NIS EXPRESSION IN TRANSFECTED CANCER CELL LINES
A. Wenzel, G. Upadhyay, U. Loos
Department of Internal Medicine I, University of Ulm, and iZKF, Ulm, Germany

14  Cancer
GAIN OF 1q IS UNIQUE TO THE TALL CELL VARIANT OF PAPILLARY THYROID CANCER
Laboratory of Epithelial Cancer Biology, Head and Neck Service, and Endocrinology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
15 Cancer
RETINOIC ACID-INDUCED STIMULATION OF SODIUM IODIDE SYMPORTER EXPRESSION AND CYTOTOXICITY OF RADIOIODINE IN PROSTATE CANCER CELLS STABLY EXPRESSING THE SODIUM IODIDE SYMPORTER UNDER THE CONTROL OF THE PROSTATE-SPECIFIC ANTIGEN PROMOTER
C. Spitzweg1, E.R. Bergert1, C.Y.F. Young2, D.J. Tindall1, J.C. Morris2
1Klinikum Grosshadern, Medizinische Klinik II, Ludwig-Maximilians-University, Munich, Germany, and Departments of 1Endocrinology and 2Urology, Mayo Clinic, Rochester, Minnesota, USA

16 Cancer
THYROID HURTHLE CELL ADENOMAS CONTAIN A DELETION MUTATION IN COXI
Research Division, General Internal Medicine, University, Bern, Switzerland

17 Cell Biology
FEEDBACK REGULATION OF ER CHAPERONES AND THYROGLOBULIN TRAFFICKING BY SECRETED THYROGLOBULIN IN CULTURED THYROCYTES
K. Kim, W. Abplanalp, S. Menon, B. Li, P. Kim
Division of Endocrinology, University of Cincinnati, Ohio, USA

18 Cell Biology
INHIBITORY INFLUENCE OF THE 3'-UNTRANSLATED REGION OF THE NIS-RNA ON THE EXPRESSION OF THE NIS GENE
Department of Internal Medicine I, University Clinic of Ulm, Germany

19 Cell Biology
2-METHOXYESTRADIOL (2-ME) INDUCES APOPTOSIS IN ANAPLASTIC THYROID CARCINOMA CELLS
P. Roswall1, S. Bu2, M. Landstrom2, N-E. Heldin1
1Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University Hospital, and 2Ludwig Institute for Cancer Research, Uppsala, Sweden

20 Cell Biology
GENES REGULATED BY TSH AND IODIDE IN CULTURED HUMAN THYROID FOLLICLES: ANALYSIS BY CDNA MICROARRAY
K. Yamazaki1, E. Yamada1, Y. Kanaji1, K. Sato1, K. Takano2, T. Obara2
1Thyroid Disease Institute, Kanaji Hospital, Kita-ku, Tokyo, and 2Institute of Clinical Endocrinology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan

21 Cell Biology
A SPECTRUM OF DEFECTIVE FOLDING AND EXPORT OF CYSTEINE MUTANTS AND NON-CYSTEINE MUTANTS OF THYROGLOBULIN CAUSING CONGENITAL GOITER
B. Li, S. Menon, S. Hossain, W. Abplanalp, P. Kim
Division of Endocrinology, University of Cincinnati, Ohio, USA
22 Cell Biology
REGULATORY MECHANISMS OF STAT-3 (Y705) PHOSPHORYLATION BY TSH IN FRTL-5 CELLS
Y.J. Park, E.S. Park, T.Y. Kim, D.J. Park, W.B. Kim, M. Shong, B.Y. Cho
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

24 Clinical
MYOSIN HEAVY CHAIN ISOFORM COMPOSITION OF SKELETAL MUSCLE IN HYPERTHYROID PATIENTS AND CHANGES IN THEIR RATIOS FOLLOWING TREATMENT
M. Brennan, J. Schimke, K. Nair
Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, Minnesota, USA

25 Clinical
THE ACUTE EFFECT OF CALCIUM CARBONATE ON THE ABSORPTION OF LEVOTHYROXINE
N. Singh, S. Weisler, J.M. Hershman
Division of Endocrinology and Metabolism, Veterans Affairs Greater Los Angeles Healthcare System, UCLA School of Medicine, Los Angeles, California, USA

26 Clinical
EXPRESSION AND FUNCTIONS OF SOMATOSTATIN RECEPTORS IN ORBITAL FIBROBLASTS FROM PATIENTS WITH GRAVES’ OPHTHALMOPATHY
O. Isozaki, T. Tsushima, Y. Nozoe, K. Kato, M. Nishimaki, M. Miyakawa, K. Takano, Y. Inoue
Department of Medicine, Tokyo Women’s Medical University, and Eye Division, Olympia Medical Clinic, Tokyo, Japan

27 Clinical
UNEXPECTED CONTRIBUTIONS BY VARIOUS FORMS OF T4 TO MEASUREMENTS OBTAINED WITH HORMONE ANALOG FREE T4 ASSAYS
Loma Linda University, School of Medicine, Loma Linda, California, and Quest Diagnostics’ Nichols Institute, San Juan Capistrano, California, USA

28 Clinical
DOES CORTICOSTEROID THERAPY MODIFY THE LONG-TERM OUTCOME OF SUBACUTE THYROIDITIS?
G. Fatourechi, J. Aniszewski, S. Jacobsen, V. Fatourechi
Mayo Clinic, Division of Endocrinology, Rochester, Minnesota, USA

30 Thyroid and the Brain
A TRANSGENIC MOUSE EXPRESSING A MUTANT (beta) THYROID HORMONE RECEPTOR SHOWS DELAY IN CEREBELLAR DEVELOPMENT
C. Cayrou, J. Martel, D. Groussel, J. Puymirat
Human Genetics Laboratory, CHUL Research Centre, Sainte-Foy, Quebec, Canada
Poster Plus (Program Numbers 5 to 40) – Regency Ballroom
These posters will be displayed from Wednesday at 3:00 pm through Friday at 1:00 pm

31 Thyroid and the Brain
ABNORMAL GROWTH OF CORTICOSPINAL AXONS INTO THE LUMBAR SPINAL CORDS OF HYT/HYT MICE WITH HYPOTHYROIDISM
J.-Y. Hsu1, S.A. Stein2,3, X.M. Xu1
1Anatomy and Neurobiology, Saint Louis University School of Medicine, St. Louis, Missouri; 2Child Neurology, Pediatric Research and Neurogenetics, Eastern Maine Medical Center, Bangor, Maine; and 3Neurology and Neurobirology, Children’s Hospital, Orange, California, USA

32 Thyroid and the Brain
TRIIODOTHYRONINE ACTS DIRECTLY ON BRAIN MITOCHONDRIA TO INDUCE RELEASE OF CYTOCHROME C INDEPENDENT OF MITOCHONDRIAL PERMEABILITY TRANSITION
R. Singh, G. Upadhayay, A. Kapoor, M.M. Godbole
S.G. Postgraduate Institute of Medical Sciences, Lucknow, India

33 Thyroid Hormone Action
DETECTION OF DEIODINASE IN HUMAN THYROID AND SKELETAL MUSCLE TISSUES USING SERA OF GUINEA PIGS IMMUNIZED AGAINST PEPTIDE CORRESPONDING TO HUMAN TYPE 2 5?-DEIODINASE
I. Molnar1, Z. Szombathy2, I. Kovacs2, J. Szentmiklosi3
1III Department of Internal Medicine and 2Department of Pathology, Kenezy County and Teaching Hospital, and 3Institute of Pharmacology, Medical University, Debrecen, Hungary

34 Thyroid Hormone Action
INCREASED UNCOUPLING PROTEIN SYNTHESIS IN BROWN FAT FROM HYPOTHYROID RATS ACCLIMATED TO COLD
A.A. Zaninovich, M. Raices, I. Rebagliati, C. Ricci, K. Hagmüller
Hospital de Clínicas and INGEBI, CONICET, Buenos Aires, Argentina

35 Thyroid Hormone Metabolism
IDENTIFICATION AND PARTIAL CHARACTERIZATION OF D3AS, A GENE TRANSCRIBED ANTISENSE FROM THE MAMMALIAN TYPE 3 DEIODINASE (DIO 3) GENE LOCUS
A. Hernandez, M.E. Martinez, W. Croteau, D.L. St. Germain
Dartmouth Medical School, Lebanon, New Hampshire, USA

36 Thyroid Hormone Metabolism
LOCALIZATION OF IODOTHYRONINE DEIODINASES TYPES I AND III IN CHICKEN CEREBELLUM
Verhoelst CHJ1,Vandenborne K1, Severi T1, Zandieh Doulabi B2, Bakker O2, Kühn ER1, Darras VM1
1Laboratory of Comparative Endocrinology, Zoological Institute, K.U. Leuven, Belgium, and 2Laboratory of Endocrinology, AMC, Amsterdam, The Netherlands

37 Thyroid Hormone Metabolism
BODY COMPOSITION IN RELATION TO TOTAL BODY POTASSIUM AND BONE MINERAL DENSITY IN HYPERTHYROIDISM
M. Dittmar, H. Reber, G.J. Kahaly
Departments of Biology/Anthropology, Nuclear Medicine, and Endocrinology/Metabolism, Gutenberg University, Mainz, Germany

Program Numbers 38, 39, and 40 have been withdrawn
3:00 - 4:00 pm  Ambassador and Regency Ballrooms

Exhibits, Poster Review, and Coffee Break

Regency Ballroom

Review of Posters:

Posters Plus (Program Numbers 5 to 40)

Program Numbers 41 to 100

Investigators available to discuss their posters

Program Numbers 41 to 100:

41  Autoimmunity

THE MECHANISM OF THYROGLOBULIN-INDUCED LYMPHOCYTIC THYROIDITIS MAY BE DIFFERENT FROM THAT OF IODIDE-INDUCED THYROIDITIS IN NONOBESE DIABETIC MICE LACKING INTERFERON REGULATORY FACTOR-1

Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University School of Medicine, Sendai, Miyagi, Japan

Program Number 42 will be displayed on Thursday, November 8 after Program Number 165

43  Autoimmunity

POLYMORPHISM OF THE CTLA-4 GENE IS ASSOCIATED WITH AUTOIMMUNE HYPOTHYROIDISM IN THE UK

J. Heward, R. Nithiyananthan, A. Allahabadia, J.A. Franklyn, S. Gough
Department of Medicine, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham, United Kingdom

44  Autoimmunity

ESTABLISH GRAVES' ANIMAL MODEL WITH GENETIC IMMUNOLOGY METHOD

H. Liu, Y. Ding, Y. Wu, Z. Mi, J. Chen, M. Luo
Shanghai Institute of Endocrinology, Shanghai, China

Program Number 45 will be displayed on Thursday, November 8 after Program Number 165

46  Autoimmunity

THYROID PEROXIDASE ANTIBODIES: THEIR RELATION TO THYROGLOBULIN ANTIBODIES IN DIFFERENTIATED THYROID CANCER

C. Guillén, A. Gauna, G. Sartorio
División Endocrinología, Hospital J. M. Ramos Mejía, Buenos Aires, Argentina
47   Autoimmunity
THE INFLUENCE OF IODINE PHYSIOLOGICAL DOSAGE ON ANTITHYROID IMMUNITY OF THE CHILDREN WITH ENDEMIC GOITER
O. Malievsky, D. Nurmukhametova
Bashkir State Medical University, Ufa, Russia

48   Autoimmunity
INTERFERON-ALPHA INDUCED PARATHYROID DYSFUNCTION
L.W. Greene, G. Tan
New York University Medical Center, New York, New York, USA

49   Cancer
ULTRASOUND-GUIDED PERCUTANEOUS ETHANOL ABLATION OF NECK NODAL METASTASES IN PATIENTS WITH PAPILLARY THYROID CARCINOMA DEFINITIVELY TREATED WITH SURGERY AND RADIOIODINE
I. Hay, W. Charboneau, B. McIver, B. Lewis, G. Thompson, C. Grant, C. Reading, J. Goellner
Mayo Clinic, Rochester, Minnesota, USA

Program Number 50 will be displayed as a Poster Plus in the #13 slot

13   Cancer
EXPRESSION OF THE RET/PTC1 ONCOGENE INHIBITS PROLIFERATION AND INDUCES APOPTOSIS OF POORLY DIFFERENTIATED HUMAN THYROID CANCER CELLS
E. Puxeddu, S. Nanni, S. Moretti, F. Moretti, A. Farsetti, M. Martinelli, A. Sacchi, F. Santeusanio, A. Pontecorvi
Department of Internal Medicine, University of Perugia; Laboratory of Molecular Oncogenesis, Regina Elena Cancer Institute, Rome; Institute of Neurobiology and Molecular Medicine, CNR, Rome; and Institute of Medical Pathology, Catholic University, Rome, Italy

51   Cancer
STABLE EXPRESSION OF RET/PTC3 IN FRTL-5 THYROID CELLS ENHANCES BASAL AND INSULIN STIMULATED ACTIVATION OF AKT/PKB
E. Miyagi, M. Saji, K.D. Burman, D. Singer, M.D. Ringel
MedStar Research Institute/Washington Hospital Center, Washington, DC, and National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

Program Number 52 has been withdrawn

53   Cancer
METASTASES FROM HURTHLE CELL THYROID CANCER ARE FAR MORE AVID FOR FLUORODEOXYGLUCOSE THAN FOR RADIOIODINE
S. Sarkar, P. Pugliese, C. Palestro
Long Island Jewish Medical Center, New Hyde Park, New York, USA
54 Cancer
PPAR-(GAMMA) IS OVER-EXPRESSED IN TYPICAL FOLLICULAR THYROID CARCINOMA, BUT NOT IN THE HURTHLE-CELL VARIANT
Division of Endocrinology, and Department of Surgical Pathology, Mayo Clinic and Foundation, Rochester, Minnesota; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA; and Department of Pathology, Wellington School of Medicine, Wellington, New Zealand

55 Cancer
PRODUCTION OF A NOVEL PEPTIDE GHRELIN BY A HUMAN MEDULLARY THYROID CARCINOMA CELL LINE
Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan

56 Cancer
HURTHLE CELL CARCINOMA METASTASES FREQUENTLY CONCENTRATE RADIOACTIVE IODINE
M. Movshovich, A. Stojadinovic, B. Singh, A. Shaha, R. Ghossein, R. Robbins, R.M. Tuttle
Memorial Sloan-Kettering Cancer Center, New York, New York, USA

57 Cancer
HER2NEU EXPRESSION IN THYROID TUMORS
Departments of 1General Surgery and 2Anesthesia, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, and 3Department of Surgery, University of California San Francisco, San Francisco, California, USA

58 Cancer
ISOLATED NECK RECURRENCE OFTEN HERALDS DISEASE PROGRESSION IN OLDER PATIENTS WITH PAPILLARY THYROID CARCINOMA
Endocrinology and Head and Neck Surgery Services, Departments of Medicine, Surgery, Pathology, and Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Program Number 59 has been withdrawn

60 Cancer
UNIQUE GENE EXPRESSION PATTERNS IN FOLLICULAR-CELL DERIVED THYROID CARCINOMA
Division of Endocrinology, Department of Surgery, and Department of Surgical Pathology, Mayo Clinic, Rochester, Minnesota, USA; and Department of Pathology, Wellington School of Medicine, Wellington, New Zealand
Wednesday, November 7, 2001
Review of Posters 41 to 100 – Regency Ballroom

61   Cancer
PRIMARY THYROID LYMPHOMAS: A 36-YEAR THYROID CANCER SERIES
J. Furlan, I. Rosen
Department of Surgery, University of Toronto, Ontario, Canada

62   Cancer
RECOMBINANT HUMAN TSH STIMULATION OF CIRCULATING THYROGLOBULIN MRNA LEVELS IN THE DETECTION OF EARLY STAGE THYROID CARCINOMA
X.W. Chen1, M. Saji1, P. Balducci-Silano1, N. Hayre1, R.M. Tuttle2, J. Anderson3, C. Spencer4, K.D. Burman1, M.D. Ringel1
1MedStar Research Institute/Washington Hospital Center, Washington, DC; 2Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York; 3Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC; 4Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA

63   Cancer
MORBIDITY FOLLOWING CENTRAL COMPARTMENT REOPERATION FOR RECURRENT OR PERSISTENT THYROID CANCER
M. Kim, S. Mandel, Z. Baloch, V. Livolsi, J. Langer, L. DiDonato, S. Fish, R. Weber
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA

64   Cancer
PERFORMANCE OF FINE NEEDLE ASPIRATION BIOPSY AND FROZEN SECTION IN WELL-DIFFERENTIATED THYROID CANCER
J. Furlan, I. Rosen
Department of Surgery, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

65   Cancer
NUMERICAL CHROMOSOMAL AMPLIFICATIONS IN HURTHLE CELL CARCINOMA OF THE THYROID BY COMPARATIVE GENOMIC HYBRIDIZATION
N. Wada, D. Miura, Q-Y. Duh, O.H. Clark
Department of Surgery, Mount Zion Medical Center, University of California San Francisco, San Francisco, California, USA

66   Cancer
PAPILLARY THYROID CARCINOMAS HARBORING RET/PTC3 REARRANGEMENTS TEN TO TWELVE YEARS AFTER THE CHERNOBYL ACCIDENT ORIGINATE PREDOMINANTLY FROM THE GOMEL REGION
J. Figge, A. Pisarchik, G. Ermak, N. Kartel
Institute of Genetics and Cytology, Minsk, Belarus

67   Cancer
PRIMARY TYPE I THYROPLASTY DURING SURGICAL MANAGEMENT OF PATIENTS WITH DIFFERENTIATED OR MEDULLARY THYROID CANCERS
G. Clayman, J. Lewin
University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
68 Cancer
CHROMOSOMAL ABNORMALITIES IN THYROID LYMPHOMA
S. Fukata\textsuperscript{1}, F. Matsuzuka\textsuperscript{1}, M. Taniwaki\textsuperscript{2}, A. Miyauchi\textsuperscript{3}, K. Kuma\textsuperscript{1}, M. Sugawara\textsuperscript{3}
\textsuperscript{1}Kuma Hospital, Kobe, Japan; \textsuperscript{2}Kyoto Prefectural University of Medicine, Kyoto, Japan; \textsuperscript{3}West Los Angeles VA Medical Center and UCLA School of Medicine, West Los Angeles, California, USA

69 Cancer
THYROID MICROCARCINOMA: FINE-NEEDLE ASPIRATION DIAGNOSIS AND HISTOLOGIC FOLLOW-UP
G.C.H. Yang, V.A. LiVolsi, Z.W. Baloch
Departments of Pathology, New York University Medical Center, New York, New York, and University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA

70 Cancer
LOW RADIATION HYPERSENSITIVITY TO THYROID CANCER
M. Woodcock\textsuperscript{1}, Y. Shi\textsuperscript{2}, M. Zou\textsuperscript{2}, M.J. Joiner\textsuperscript{1}, N.R. Farid\textsuperscript{3}
\textsuperscript{1}Grey Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom; \textsuperscript{2}King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; and \textsuperscript{3}Osancor Biotech Inc., Watford, Herts, United Kingdom

71 Cancer
SIMILAR RECURRENCE RATES IN PATIENTS WITH DIFFERENTIATED THYROID CANCER TREATED WITH LOBECTOMY VERSUS EXTENSIVE SURGERY: EXPERIENCE IN A COMMUNITY HOSPITAL
R. Sievert\textsuperscript{1}, S. Aytug\textsuperscript{1}, R. Amani-Yazdi\textsuperscript{2}, S. Pollack\textsuperscript{3}, L.E. Shapiro\textsuperscript{1}, F.A. Ross\textsuperscript{4}
\textsuperscript{1}Division of Endocrinology and Metabolism, Winthrop-University Hospital, SUNY School of Medicine at Stony Brook, Mineola, New York; \textsuperscript{2}Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, North Carolina; \textsuperscript{3}Department of Decision Sciences, St. John’s University, Jamaica, New York; \textsuperscript{4}Department of Medicine, Mount Sinai School of Medicine, Elmhurst Hospital, Elmhurst, New York, USA

72 Cell Biology
TIE-2 AND ANGIOPOIETIN-1 EXPRESSION IN HUMAN THYROID TUMORS
N. Mitsutake, H. Namba, K. Ishigaki, H. Ayabe, S. Yamashita
Nagasaki University School of Medicine, Nagasaki, Japan

73 Cell Biology
REGULATION OF THE THYROID NA\textsuperscript{+}/I\textsuperscript{-} CO-TRANSPORTER BY THYROTROPIN AND IODINE IN VIVO
Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Program Number 74 has been withdrawn
75  Cell Biology
THE ANCIENT EVOLUTIONARY ORIGIN OF THE THYROTROPIN RECEPTOR C-FLANKING “ADD ON” SEQUENCES
V. Kaczur1, I.A. Racz2, N.R. Farid1
1Osancor Bionformatics Ltd, Watford, Herts, United Kingdom, and 2Department of Evolutionary Zoology, University of Debrecen, Debrecen, Hungary

76  Cell Biology
GENETIC FACTORS IN SPORADIC NON-TOXIC GOITER: LACK OF ASSOCIATION WITH IMMUNE RESPONSE GENES
A. Allahabadia, J. Heward, R. Nithiyananthan, S. Gibson, J.A. Franklyn, S. Gough
Division of Medical Sciences, University of Birmingham, Birmingham, United Kingdom

77  Clinical
SYSTEMATIC STUDIES OF FREE T4 METHODOLOGIES USING CLINICALLY RELEVANT MODELS OF T4 VARIABILITY
J.C. Nelson, R. Wang, R.B. Wilcox
Loma Linda University School of Medicine, Loma Linda, California, and Quest Diagnostics’ Nichols Institute, San Juan Capistrano, California, USA

78  Clinical
MEASUREMENT OF FREE T4 (FT4) LEVELS IN PRETERM (PT) INFANTS RECEIVING HEPARIN-SUPPLEMENTED PARENTERAL NUTRITION (HSPN): COMPARISON BETWEEN EQUILIBRIUM DIALYSIS (ED) AND A TWO-STEP RIA (2-RIA) METHOD
J.S. Dallas1, D.V. Dallas1, P.H. Frost2, C. Cochran1, P. Clements1
1University of Texas Medical Branch, Galveston, Texas, and 2University of California, San Francisco, California, USA

79  Clinical
DIAGNOSIS AND TREATMENT OF GRAVES’ PATIENTS WITH UNDETECTABLE TSH RECEPTOR ANTIBODIES (TRAB) DETERMINED BY PORCINE THYROCYTES: COMPARISON WITH TRAB AND THYROID HORMONE-RELEASING ACTIVITY DETERMINED BY HUMAN THYROCYTES
Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan

80  Clinical
THYROTOXICOSIS FACTITIA CAUSED BY DIET PILLS
H. Ohye, S. Fukata, M. Kanoh, S. Kubota, A. Miyauuchi, K. Kuma
Kuma Hospital, Kobe, Japan

81  Clinical
EVALUATING VARIATIONS OF BIOLOGICAL INDICATORS ON SUBJECTS USING ORAL IODIZED OIL FOR THE TREATMENT AND PREVENTION OF ENDEMIC GOITER IN VIETNAM
H. Uoc1, T. Nguyen1, Q. Luong1, P. Singer2
1Endocrine Hospital, Hanoi, Republic of Vietnam, and 2University of Southern California School of Medicine, Los Angeles, California, USA
82 Clinical
THREE YEARS EXPERIENCE WITH THE DANISH HYPER- AND HYPOTHYROIDISM REGISTER
I. Bülow Pedersen¹, P. Laurberg¹, N. Knudsen², T. Jørgensen³, H. Perrild², L. Ovesen⁴
¹Department of Endocrinology and Medicine, Aalborg Hospital; ²Medical Clinic 1, Bispebjerg Hospital; ³Centre of Preventive Medicine, Glostrup Hospital; and ⁴Danish Veterinary and Food Administration, Denmark

83 Clinical
PREDICTIVE VALUES OF PRETREATMENT TSH RECEPTOR ANTIBODIES IN PREDICTION FOR CLINICAL COURSES OF GRAVES’ DISEASE TREATED WITH METHIMAZOLE
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

84 Clinical
PERCUTANEOUS ETHANOL INJECTION (PEI) TREATMENT FOR GRAVES’ DISEASE: THREE-YEAR FOLLOW-UP STUDY
T. Yokozawa, A. Miyauchi, K. Kuma, S. Fukata, F. Matsuzuka, H. Ohye, T. Yokozawa
Kuma Hospital, Kobe, Japan

85 Clinical
THYROID SIZE IS INCREASED DESPITE SUFFICIENT IODINE INTAKE AND GOOD NUTRITION. CAN THIS BE DUE TO THE EFFECT OF GOITROGENS OR JUST A RESIDUAL EFFECT OF IDD FOR A PROLONGED PERIOD?
S. Brahmbhatt, R. Brahmbhatt, C. Eastman, S. Boyages
Fremantle Hospital, Fremantle, Australia

86 Clinical
TRIODO THYRONINE (T3) SUPPLEMENTATION CAN HELP PATIENTS WITH HYPOTHALAMIC OBESITY TO LOSE WEIGHT
R. Sellin, M. Klein
University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

87 Clinical
RELATIONSHIP OF GESTATIONAL AGE WITH THE NEONATAL URINARY IODINE EXCRETION AND THE THYROID VOLUME
I. Molnar¹, L. Csathy², G. Szasz²
¹III Department of Internal Medicine, ²Department of Pediatrics, and ³Department of Radiology, Kenezy County and Teaching Hospital, Debrecen, Hungary

88 Clinical
INFLUENCING HEALTH CARE POLICIES WITH PUBLIC THYROID AWARENESS CAMPAIGNS IN BRAZIL: ITS IMPACT FOR THE POPULATION AND FOR THYROIDOLOGISTS
Brazilian Society of Endocrinology and Metabolism (SBEM), Brazil
89   Clinical
INDICATORS FOR THE ASSESSMENT OF IODINE DEFICIENCY DISORDERS IN
BASHKORTOSTAN
O. Malievsky
Bashkir State Medical University, Ufa, Russia

90   Clinical
PATHOMORPHOSIS OF DIFFUSE NONTOXIC GOITER AMONG CHILDREN
UNDER SALT IODIZATION PROGRAMME
O. Malievsky, D. Nurmukhametova
Bashkir State Medical University, Ufa, Russia

91   Clinical
IS HYPOTHERMIA USEFUL FOR SURGERY OF UNCONTROLLED SEVERE
GRAVES’ HYPERTHYROIDISM?
H. Kurihara, J. Sasaki, S. Tanimura
Kurihara Thyroid Clinic, Morioka, Iwate, Japan

92   Thyroid Hormone Action
THE EFFECT OF TRIIODOTHYRONINE ON GROWTH PARAMETERS AND CELL
CYCLE REGULATORS IN THYROID HORMONE RESPONSIVE AND
NONRESPONSIVE THYROTROPIC TUMORS
W.W. Woodmansee, V.D. Sarapura, D.J. Haakinson, J.M. Dowding, A.R. Gordon, D.F. Gordon,
W.M. Wood, E.C. Ridgway
University of Colorado Health Sciences Center, Denver, Colorado, USA

93   Thyroid Hormone Action
COMPARATIVE EFFECTS OF THE THYROID HORMONE-BETA1 SELECTIVE
AGONIST GC-1 or 3,5,3'-triiodo-L-THYRONINE (T3) ON CHOLESTEROL,
METABOLIC RATE AND HEART RATE IN RATS
G. Grover1, L. Sparano1, P. Sleph1, S. Adolfsen1, M. Smith1, T. Scanlan2, J. Baxter2
1Bristol-Myers Squibb, Pennington, New Jersey, and 2University of California San Francisco, San
Francisco, California, USA

94   Thyroid Hormone Action
A NOVEL ASSAY TO MEASURE THYROID HORMONE-MEDIATED CARDIAC
SPECIFIC GENE TRANSCRIPTION
S. Danzi, K. Ojamaa, I. Klein
North Shore-Long Island Jewish Research Institute/New York University School of Medicine,
Manhasset, New York, USA

Program Number 95 has been withdrawn

96   Thyroid Hormone Action
NEUROPEPTIDE Y SUPPRESSED TRIIODOTHYRONINE-INDUCED RISE IN
MITOCHONDRIAL RESPIRATION IN BROWN FAT OF HYPOTHYROID RATS
I. Rebagliati, C. Ricci, A.A. Zaninovich, C. Tang
University of Hong Kong and the University of Buenos Aires, Argentina
Program Number 97 has been withdrawn

98  Thyroid Hormone Metabolism
CENTRAL, ORGAN-LEVEL AND CELLULAR THYROID HORMONE REGULATION DYNAMICS: NORMAL AND “DYNAMIC DISEASE” BEHAVIOR, INCLUDING OSCILLATIONS AND CHAOS
J.J. DiStefano III, A. Chen
Biocybernetics Laboratory, University of California Los Angeles, Los Angeles, California, USA

99  Thyroid Hormone Metabolism
LEVOTHYROXINE THERAPY AND SERUM FREE THYROXINE AND FREE TRIIODOTHYRONINE CONCENTRATIONS
K.A. Woeber
Division of Endocrinology, University of California San Francisco, San Francisco, California, USA

100 Thyroid Hormone Metabolism
A STUDY OF ENDEMIC GOITER IN THE RUSSIAN NORTH-EAST
A. Gorbachev
International Scientific Center «Arktika», Russian Academy of Sciences, Magadan, Russia

136  Cancer
ACCURACY OF FINE NEEDLE ASPIRATION BIOPSY IN NODULAR THYROID DISEASES
J. Furlan, I. Rosen
Department of Surgery, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

203  Cancer
SURGICAL MANAGEMENT FOR SUSPICIOUS CYTOLOGY OF NON-PAPILLARY THYROID NODULE BY FINE NEEDLE ASPIRATION BIOPSY
I.B. Rosen, J.C. Furlan
Department of Surgery, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
Wednesday, November 7, 2001
Afternoon Session and Evening

4:00 - 5:00 pm  Regency Ballroom

The Arthur Bauman Clinical Symposium
ATA established the fund for this Symposium in celebration and memory of the professional accomplishments and personal qualities of Dr. Arthur Bauman, a master clinician and clinical investigator. The Symposium presents advances in clinical investigation in thyroidology, and promotes participation by younger members of the Association.

T3 and IQ: From Brain Development to Care of the Pregnant Patient
Chair: Kenneth D. Burman

- Thyroid Hormone and Brain Development  Grant W. Anderson
- Pregnancy and Thyroid Status  Gregory A. Brent
- Maternal Thyroid Deficiency and Cognitive Function of the Child  Robert Z. Klein

Supported by an educational grant from Abbott Laboratories

5:00 - 6:15 pm  Meet the Professor Workshop Suppers
Advance purchase required; admission by ticket only

Diplomat Room
Subclinical Hyperthyroidism
Douglas Ross
Supported by an educational grant from Abbott Laboratories

Cabinet Room
Cytokines and Their Influence on Thyroid Function
James R. Baker, Jr.

Forum Room
Extra-Nuclear Mechanism of Thyroid Hormone Action
Paul J. Davis

Council Room
Treatment of Low T3 in NTI: Pros and Cons
Leslie J. DeGroot and Inder J. Chopra

Directors’ Room
A Program for I-131 Dosimetric Treatment of Cancer Patients
Stephanie L. Lee

6:30 - 8:00 pm  Palladian Room and Terrace
Welcome Reception
[this page is intentionally left blank so that Thursday’s program can begin on an even-numbered page. this page is not to be printed. it’s included just as a reminder that a blank page goes here]
Special Program
Thursday, November 8, 2001

6:00 - 7:45 am Palladian Room
Sunrise “Early Riser” Seminar: Case Challenges and Clinical Conundrums
Chair: Peter A. Singer
Faculty: Lewis E. Braverman
E. Chester Ridgway
Leonard Wartofsky

Sponsored by The Endocrine Society
Supported by an unrestricted educational grant from Abbott Laboratories
Thursday, November 8, 2001

8:00 - 9:30 am  Regency Ballroom

Plenary Session – Topic Highlights
Oral Abstract Presentations
Chairs: James R. Baker, Jr. and John C. Morris, III

101  8:00 am  Cancer
RADIOIODIDE THERAPY IN hNIS TRANSFECTED HUMAN FOLLICULAR THYROID CARCINOMA
J.W.A. Smit, J.P. Schroder-van der Elst, M. Karperien, J.A. Romijn, D. van der Heide
Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands

102  8:15 am  Cancer
GENE THERAPY USING THE THYMIDINE KINASE-GANCYCLOVIR (TK/GCV) SYSTEM AND MOUSE INTERLEUKIN 12 IN A HUMAN THYROID TUMOR MODEL
R. Zhang1, F.H. Straus2, L.J. DeGroot1
1Thyroid Study Unit/MC 3090, Department of Medicine, and 2Department of Pathology, University of Chicago, Chicago, Illinois, USA

103  8:30 am  Autoimmunity
GENE EXPRESSION PROFILING OF GRAVES' OPHTHALMOPATHY AND GRAVES' DISEASE TISSUES USING DNA ARRAY ANALYSIS: PRELIMINARY RESULTS
C.M. Dutton, R.S. Bahn
Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic/Foundation, Rochester, Minnesota, USA

104  8:45 am  Autoimmunity
NEUTRALIZATION OF AUTOANTIBODIES USING A TSH RECEPTOR A SUBUNIT ‘MODULE’: EVIDENCE FOR GREATER EPITOPIC HETEROGENEITY IN BLOCKING THAN IN STIMULATING AUTOANTIBODIES
L. Schwarz-Lauer, G.D. Chazenbalk, S.M. McLachlan, Y. Ochi, Y. Nagayama, B. Rapoport
Autoimmune Disease Unit, Cedars-Sinai Research Institute, Los Angeles, California, USA; Research Institute for Production Development, Kyoto, Japan; and Department of Pharmacology, University of Nagasaki School of Medicine, Nagasaki, Japan

105  9:00 am  Autoimmunity
NEW STUDIES ON THE PRESENCE AND THE DISTRIBUTION OF THYROGLOBULIN (Tg) IN ORBITAL TISSUES (OT) FROM PATIENTS WITH THYROID-ASSOCIATED OPHTHALMOPATHY (TAO)
S. Lisi, M. Marino, B. Mazzi, C. Di Cosmo, S. Sellari-Franceschini, A. Pinchera, L. Chiovato
Department of Endocrinology, University of Pisa, Pisa, Italy
Thursday, November 8, 2001
Morning Session and Review of Posters 107 to 165 – Regency Ballroom

106 9:15 am  Autoimmunity
THE CLUSTERING OF AUTOIMMUNE THYROID DISEASE IN THE TYPE 1 DIABETES WARREN REPOSITORY
Division of Medical Sciences, Birmingham Heartlands Hospital, University of Birmingham, Birmingham, UK

9:30 - 10:00 am  Ambassador and Regency Ballrooms
Exhibits, Poster Review, and Coffee Break
Regency Ballroom
Review of Posters:
Program Numbers 5 to 40 (Poster Plus)
Program Numbers 107 to 165
Investigators available to discuss their posters

Program Numbers 107 to 165:

107  Autoimmunity
ORBITAL CONNECTIVE TISSUE EXPANSION IS NOT A MAJOR CONTRIBUTOR TO PROPTOSIS: VOLUMETRIC MRI IN ENDOCRINE OPHTHALMOPATHY
Z. Szucs-Farkas1, J. Toth1, L. Galuska2, L. Tron3, E. Balazs4, E.V. Nagy5
Departments of 1Radiology, 2Nuclear Medicine, 3PET, 4Ophthalmology, and 5Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary

108  Autoimmunity
VALUE OF RECOVERY DETERMINATION FOR THYROGLOBULIN MEASUREMENT IN SERA FROM PATIENTS WITH GRAVES’ DISEASE
C. Massart, D. Maugendre
Service d’ Hormonologie, CHU Pontchaillou, Rennes, France

109  Autoimmunity
THE FREQUENCY OF POSITIVE TGABS AND NEGATIVE TPOABS IS HIGH IN AUTOIMMUNE THYROIDITIS ASSOCIATED WITH THYROID NODULES
P. De Remigis, F. Ruscitti, L. Vianale
Thyroid and Endocrine Unit, General Hospital, Chieti, Italy

110  Autoimmunity
CLINICAL VALUE OF THYROGLOBULIN AND ANTI-TPO ANTIBODY MEASUREMENTS ASSOCIATED WITH BINDING TSH RECEPTOR ANTIBODY DETERMINATION IN PATIENTS WITH GRAVES’ DISEASE
D. Maugendre, C. Massart
Unité d’Endocrinologie, CHU de Rennes, France
111  Autoimmunity
INTERACTIONS OF HLA-DRB4 AND CTLA-4 GENES INFLUENCE THYROID FUNCTION IN HASHIMOTO’S THYROIDITIS IN JAPANESE
Department of Medicine, Keio University, and Nerima General Hospital, Tokyo, Japan

112  Autoimmunity
ASSOCIATION OF GRAVES’ DISEASE WITH INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE AMONG CHINESE
H. Liu, Y. Ding, Y. Wu, Z. Mi, J. Chen, M. Luo
Shanghai Institute of Endocrinology, Shanghai, China

113  Autoimmunity
SUCCESSFUL USE OF RALOXIFEN IN THE TREATMENT OF RIEDEL’S THYROIDITIS
H. Niepomnisczce, A. Safenraiter, A. Diaz, A. Pignatta, O.D. Bruno
Division of Endocrinology, Hospital de Clinicas, University of Buenos Aires, Buenos Aires, Argentina

115  Cancer
I-124/PET FOR THE DETECTION AND DOSIMETRY OF RESIDUAL DIFFERENTIATED THYROID CARCINOMA
Memorial Sloan-Kettering Cancer Center, New York, New York, USA

116  Cancer
USE OF MECHANICAL DISSOCIATION DEVICE AND THYROGLOBULIN LABELING IN THE FLOW CYTOMETRIC DNA MEASUREMENT OF FRESH, FROZEN THYROID SAMPLES
Departments of Surgery, Medicine, and Pathology, and Institute of Psychology, University of Debrecen, Hungary

117  Cancer
ADENOVIRUS-MEDIATED TRANSFER OF THE TTF-1 GENE RESTORES DIFFERENTIATION OF HUMAN THYROID CARCINOMA
F. Furuya, H. Shimura, H. Suzuki, A. Miyazaki, T. Endo, K. Haraguchi, T. Onaya
Third Department of Internal Medicine, Yamanashi Medical University, Tamaho Yamanashi, Japan

118  Cancer
APPLICATION OF THE CRE-LOXP SYSTEM TO ENHANCE THYROID-TARGETED EXPRESSION OF SODIUM/IODIDE SYMPORTER
X. Lin, E. Mazaferri, S. Jhiang
Department of Physiology, Ohio State University, Columbus, Ohio, USA
119  Cancer
ADENOVIRUS-MEDIATED TTF-1 GENE TRANSFER INDUCES CELL DEATH IN THYROID CANCER CELLS AND INHIBITS TUMOR GROWTH IN NUDE MICE
H. Suzuki, H. Shimura, F. Furuya, A. Miyazaki, K. Haraguchi, T. Endo, T. Onaya
Third Department of Internal Medicine, Yamanashi Medical University, Yamanashi, Japan

120  Cancer
THYROID CANCER POST-CHERNOBYL: AN OPPORTUNITY FOR INTERNATIONAL COLLABORATION
G.A. Thomas, E.D. Williams
TCRG, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom

121  Cancer
GENOMIC ANALYSIS OF GENE AMPLIFICATION IN POST-CHERNOBYL PAPILLARY THYROID CARCINOMA
R. Kimmel1, R.M. Tuttle2, C. Cheng1, D. Nguyen1, S. Lee1, L-P. Zhao1, S. Davis1, P. Neiman1
1Fred Hutchinson Cancer Research Center, Seattle, Washington; 2Endocrinology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

122  Cancer
INHIBITION OF CANCER CELL GROWTH IN THYROID CANCER CELL LINES BY TROGLITAZONE, THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA AGONIST
J. Park, M. Wong, Q. Duh, O.H. Clark
Department of Surgery, University of California San Francisco/Mount Zion Medical Center, San Francisco, California, USA

123  Cancer
DIFFERENTIATED THYROID CARCINOMA TREATED WITH RADIOIODINE: SERIAL EVALUATION OF SERUM TG AND QUANTITATIVE RT-PCR OF CIRCULATING TG mRNA
I.G.S. Rubio, R. Romão, A. Gryga, M.S. Cardia, C. Buchpiguel, M. Knobel, G. Medeiros-Neto
Division of Endocrinology and Department of Radiology, University of São Paulo Medical School, São Paulo, SP, Brazil

124  Cancer
ASSESSING THE EFFECTS OF THYROID HORMONE SUPPRESSION THERAPY (THST) ON ADVERSE CLINICAL OUTCOMES IN THYROID CANCER (THYRCA): A QUANTITATIVE RESEARCH SYNTHESIS
N. McGriff, G. Csako, L. Guthrie, L. Gourgiotis, F. Pucino, N.J. Sarlis
Pharmacy Department, Clinical Center, and Clinical Pathology, Clinical Center, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
125 Cancer PROGNOSTIC SCORING SYSTEM IN PATIENTS WITH FOLLICULAR THYROID CANCER A. D'Avanzo, P.H.G. Ituarte, P. Treseler, E. Kebebew, J. Wu, N. Perrier, A.E. Siperstein, Q.Y. Duh, O.H. Clark Departments of Surgery and Pathology, Mount Zion Medical Center/University of California San Francisco, San Francisco, California, USA

126 Cancer FOLLICULAR CARCINOMA AS AN ENTIRE AUTONOMOUS FUNCTIONING THYROID NODULE (AFTN), PRESENTING AN Ile 620 ACTIVATING MUTATION OF THE THYROTROPIN RECEPTOR AND A cys 12 MUTATION OF THE Ki-RAS H. Niepomniszcze, H. Suarez, A. Pignatta, K. Danilowicz, M. Manavela, B. Elsner, O.D. Bruno Divisions of Endocrinology and Pathology, Hospital de Clinicas-UBA, Buenos Aires, Argentina, and Laboratoire de Genetique Moleculaire (UPR 42), Institut de Recherches sur le Cancer (IFC 01), CNRS, Villejuif Cedex, France

127 Cancer PREDICTING THE SERUM THYROGLOBULIN LEVEL ATTRIBUTABLE TO THE POSTOPERATIVE THYROID TISSUE REMNANT M. Morocco, R. Kloos, H. Nagaraja Internal Medicine and Radiology; Divisions of Endocrinology, Diabetes and Metabolism and Nuclear Medicine; and Department of Statistics, Ohio State University, Columbus, Ohio, USA

128 Cancer THERAPEUTIC USE OF RECOMBINANT TSH IN 12 PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA H. Graf, M.S. Marone, C. Almeida Federal University of Parana, Parana, Brazil

129 Cancer SUSCEPTIBILITY OF THYROID CANCER CELLS TO UCN-01-INDUCED APOPTOSIS CORRELATES WITH Bcl-2 PROTEIN LEVEL S.H. Wang, E. Phelps, S. Utsugi, J.R. Baker, Jr. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA

130 Cancer SERUM THYROGLOBULIN IN SUBJECTS WITH THYROID CANCER, DIFFUSE AND NODULAR GOITER, AND LOW URINE IODINE CONTENT: EXPERIENCE FROM THE UKRAINE-USA CHERNOBYL THYROID DISEASE COHORT STUDY (CTDCS) M. Tronko¹, O. Bolshova¹, O. Epshtein¹, V. Kravchenko¹, Z. Lysova¹, O. Lyutkevych¹, V. Oliynyk¹, O. Rakov¹, I. Savosko¹, G. Terekhova¹, A.B. Brill², D. Fink², E. Greenebaum², I. Masnyk¹, R.J. McConnell³, J. Robbins³ ¹Research Institute of Endocrinology and Metabolism, Kyiv, Ukraine; ²Vanderbilt University, Nashville, Tennessee; ³Columbia University, New York, New York; and ⁴National Cancer Institute and ⁵National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Rockville, Maryland, USA
131 Cancer EXPRESSION OF H-RAS AND K-RAS PROTOONCOGENES IN NODULAR GOITER
L. Golbert, A.L. Maia
Division of Endocrinology, Hospital de Clínicas de Porto Alegre, UFRGS, Brazil

132 Cancer WHEN FINE-NEEDLE ASPIRATION IS NOT ENOUGH: THE ROLE OF CLINICAL DIAGNOSIS IN THYROID CARCINOMA
M. Yeh, O. Demircan, P. Ituarte, O.H. Clark
Department of Surgery, University of California San Francisco/Mt. Zion Medical Center, San Francisco, California, USA

133 Cancer DIFFICULTIES IN THE DIAGNOSIS OF MEDULLARY THYROID CARCINOMA: REPORT OF 3 CASES
R. Camargo, E. Tomimori, E. Sakane, V. Alves, G. Medeiros-Neto
Thyroid Unit, Endocrine Division, Sao Paulo University School of Medicine, Sao Paulo, Brazil

134 Cancer CAN WE RELY ON PATHOLOGIC PARAMETERS TO DEFINE CONSERVATIVE TREATMENT OF PAPILLARY THYROID CARCINOMA?
M. Paessler, F. Kreisel, V.A. LiVolsi, L.A. Akslen, Z.W. Baloch
Departments of Pathology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA, and The Gade Institute, Haukeland Hospital, University of Bergen, Norway

135 Cancer ASSESSMENT OF SERUM THYROGLOBULIN LEVELS BEFORE SURGERY IN BENIGN AND MALIGNANT THYROID NODULES: ITS POTENTIAL ROLE FOR DIFFERENTIAL DIAGNOSIS
Sao Paulo University School of Medicine, Sao Paulo, Brazil

Program Number 136 will be displayed on Wednesday, November 7 after Program Number 100

138 Cell Biology THYROID HORMONE AND OLEIC ACID REGULATE UCP3 GENE EXPRESSION IN SKELETAL MUSCLE DERIVED CELL LINES SUBMITTED TO CALCINURIN INHIBITION
M. Christoffiolette¹, A. Moriscot²
¹Department of Physiology and Biophysics, and ²Department of Histology and Embryology, ICB, University of São Paulo, Brazil
139  Cell Biology
IMPACT OF C-TERMINAL MUTATIONS ON THE SECRETION OF THYROXINE-BINDING GLOBULIN
L.C. Moeller, A. Fingerhut, S.D. Knuedeler, A.H. Oeffner, K. Mann, O.E. Janssen
Department of Endocrinology, Center of Internal Medicine, University of Essen, Essen, Germany

140  Cell Biology
CLONING OF THE MOUSE SODIUM IODIDE SYMPORTER
L. Pinke, D. Dean, E. Bergert, C. Spitzweg, C. Dutton-Gibbs, J. Morris
Department of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA

141  Clinical
A SURVEY ON THE ETIOLOGY OF RESISTANCE TO THYROID HORMONE
K. Dennis, J. Pohlenz, A. Dimutrescu, P. Sadow, M. Darin, R. Szmulewitz, R.E. Weiss, S. Refetoff
Departments of Medicine and Pediatrics, University of Chicago, Chicago, Illinois, USA

142  Clinical
LOW GOITRE PREVALENCE AMONG USERS OF ORAL CONTRACEPTIVES IN A LARGE POPULATION SAMPLE
N. Knudsen, I. Bulow, P. Laurberg, H. Perrild, L. Ovesen, T. Jorgensen
Medical Clinic I, Bispebjerg University Hospital, Copenhagen, Denmark

143  Clinical
INTRAOPERATIVE ULTRASOUND AS AN ADJUNCT TO PALPATION IN NECK EXPLORATION FOR METASTATIC THYROID CANCER: A PRELIMINARY REPORT
C. Vakili¹, K. Vakili²
¹University of Massachusetts Medical Center, Worcester, Massachusetts, and Heywood Hospital, Gardner, Massachusetts, and ²Boston University School of Medicine, Boston, Massachusetts, USA

Program Number 144 has been withdrawn

145  Clinical
DETERMINATION OF THE TIME REQUIRED FOR RECOVERY OF THE THYROID RADIOIODINE UPTAKE (RIU) FROM COMPETITIVE INHIBITION BY LARGE DOSES OF PERCHLORATE
M.A. Greer, S.E. Greer
Division of Endocrinology, Department of Medicine, Oregon Health Sciences University, Portland, Oregon, USA
Program Number 146 has been withdrawn

147 Clinical
PAINFUL HASHIMOTO'S THYROIDITIS AS AN INDICATION FOR THYROIDECTOMY
Y. Kon, L.J. DeGroot
Thyroid Study Unit, University of Chicago, Chicago, Illinois, USA

148 Clinical
DISCORDANCE OF MEDIAN URINE IODINE VALUES WITH THYROID VOLUMES OF PRIMARY SCHOOL CHILDREN IN AUSTRALIA: IMPLICATIONS FOR THE MONITORING OF IODINE STATUS IN DEVELOPED ECONOMIES
K. Guttikonda, C. Travers, P. Lewis, S. Boyages
Department of Diabetes and Endocrinology, Westmead Hospital, Westmead, NSW, and Central Coast Area Public Health Unit, Gosford, NSW, Australia

149 Clinical
CTLA-4 GENE POLYMORPHISM DOES NOT CONFER SUSCEPTIBILITY TO THYROID-ASSOCIATED OPHTHALMOPATHY IN JAPANESE
Y. Hiromatsu, T. Fukutani, S. Murayama, H. Kaku, I. Miyake, Z. Makita
Department of Endocrinology and Metabolism, Kurume University School of Medicine, Japan

150 Clinical
THE USE OF A RAPID AUTOMATED PARATHYROID HORMONE (PTH) IMMUNOASSAY FOR INTRAOPERATIVE PTH MEASUREMENTS ON ELECSYS 2010
S. Saw, R. Khoo, B. Saw, W.K. Cheah, T.C. Aw
Department of Laboratory Medicine, National University Hospital, Singapore

151 Clinical
THYROID GLAND VOLUME, IODINE EXCRETION AND TYPE OF FEEDING IN NEWBORNS
I. Molnár¹, L. Csáthy², G. Szasz³, J. Math⁴
¹Department of Pediatrics, ²Department of Radiology, and ³III Department of Internal Medicine, Kenézy County and Teaching Hospital, and ⁴Institute of Psychology, University of Debrecen, Debrecen, Hungary

152 Clinical
IODINE DEFICIENCY DISEASE IN THE DOMINICAN REPUBLIC
M. Chaudhari, T. Malasanos, A. Selman-Almonte, L. Pagan, S. Pino, M. Previti, L.E. Braverman, A. Rosenbloom
Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida, and Boston Medical Center, Boston, Massachusetts, USA
Review of Posters 107 to 165 – Regency Ballroom

153  Clinical
EVALUATING THE DOSE SELECTION PROCESS FOR RADIOACTIVEIODINE TREATMENT IN PATIENTS WITH HYPERTHYROIDISM
H. Baskin, L. Gordon
Medical University of South Carolina, Charleston, South Carolina, USA

154  Clinical
EVOLUTION OF THE THYROID FUNCTION POST RADIOIODINE-131 IN PATIENTS WITH GRAVES’ HYPERTHYROIDISM
L. Luna, C. Zea, E. Aliaga, A. Vicharra, D. Huapaya
Service of Endocrinology and Nuclear Medicine, National Hospital Guillermo Almenara Irigoyen, Lima, Peru

155  Clinical
MONONEUROPATHY IN THYROTOXICOSIS
S. Mukherjee, P.J. Weston
Department of Diabetes and Endocrinology, Royal Liverpool University Hospital, Liverpool, United Kingdom

157  Thyroid Hormone Action
THYROID HORMONE DOWN REGULATES ADENOVIRUS 5 E1A AND SWI/SNF DEPENDENT GENE ACTIVATION IN YEAST BY THE HUMAN THYROID HORMONE RECEPTOR
X. Meng, Y. Yang, X. Cao, J. Mymryk, P. Walfish
Samuel Lunenfeld Research Institute of Mount Sinai Hospital and Department of Medicine, University of Toronto Medical School, Toronto, Ontario, Canada

158  Thyroid Hormone Action
IMPACT OF OVERT HYPERTHYROIDISM ON LEFT VENTRICULAR CHAMBER FUNCTION AND MYOCARDIAL MECHANICS IN HUMANS
B. Biondi, E.A. Palmieri, S. Fazio, M. Pulcrano, F. Affuso, V. Palmieri, G. Lombardi
University Federico II School of Medicine, Naples, Italy

159  Thyroid Hormone Action
TRIODOTHYRONINE REGULATES THE TRANSCRIPTION OF KERATIN GENES IN A PATTERN ASSOCIATED WITH EPIDERMAL PROLIFERATION
J.D. Safer, L.M. Fraser, M. Hoa, S. Ray, M.F. Holick
Section of Endocrinology, Diabetes and Nutrition, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA

160  Thyroid Hormone Action
DIFFERENTIAL ABUNDANCE OF ENDOGENOUS THYROID HORMONE RECEPTOR ISOFORMS MEDIATES VARIABLE PHENOTYPIC EXPRESSION IN RESISTANCE TO THYROID HORMONE (RTH)
M. Kaneshige, Y. Kamiya, S.-y. Cheng
National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
161  Thyroid Hormone Action
SEQUENTIAL ULTRASTRUCTURAL MODIFICATIONS IN THE HEART OF HYPERTHYROID RATS
P. Ferreira, C. L'Abatte, P. Abrahamsohn, E. Kimura, A. Moriscot
Department of Histology and Embryology ICB, USP, São Paulo, Brazil

162  Thyroid Hormone Metabolism
PARTIAL DEFICIENCY OF THYROXINE-BINDING GLOBULIN DUE TO A MUTATION IN THE SIGNAL PEPTIDE
S.D. Knuedeler, S. Reutrakul, C. Greenlee, A. Fingerhut, S. Refetoff, O.E. Janssen
Department of Endocrinology, Center of Internal Medicine, University of Essen, Germany; Departments of Medicine and Pediatrics, University of Chicago, Chicago, Illinois, and Allentown, Pennsylvania, USA

163  Thyroid Hormone Metabolism
5’DEIODINASE TYPE I (D1) IN THE BREAST CANCER CELL LINE MCF-7 IS STIMULATED BY RETINOIC ACIDS (ALL TRANS AND 9 CIS) BUT NOT BY TRIIODOTHYRONINE AND ISONPROTERENOL
P. Garcia-Solis, E. Gallardo de la O, C. Aceves
Centro de Neurobiologia, UNAM, Queretaro, Mexico

164  Thyroid Hormone Metabolism
SPECIFICITIES OF HUMAN HYDROXYSTEROID SULFOTRANSFERASE 2B1a (SULT2B1a) AND MUTANT SULT2B1a ENZYMES FOR THYROID HORMONES AND DEHYDROEPIANDROSTERONE (DHEA)
X-Y. Li1,3, D. Clemens1,2, R. Anderson1,3
1VA and 2University of Nebraska Medical Centers, and 3Creighton University School of Medicine, Omaha, Nebraska, USA

165  Thyroid Hormone Metabolism
STUDY ON THE THYROID STATUS IN RATS DURING THE MONTH FOLLOWING SINGLE EXTERNAL GAMMA-IRRADIATION
Z. Niatsetskaya, L. Nadolnik
Laboratory of Endocrine Glands Biochemistry of the Institute of Biochemistry, National Academy of Sciences, Grodno, Belarus

42   Autoimmunity
THE THYROGLOBULIN GENE IS A MAJOR GENE FOR AUTOIMMUNE THYROID DISEASE
Y. Tomer, D.A. Greenberg, E.S. Concepcion, T.F. Davies
Division of Endocrinology and Metabolism, Department of Medicine, and Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA

45   Autoimmunity
EXPRESSION OF FULLY FUNCTIONAL RECOMBINANT HUMAN CTLA4 AND ITS INHIBITORY EFFECT ON INTRINSIC IL-2: ROLE OF A SIGNAL PEPTIDE POLYMORPHISM
Y. Xu, P.N. Graves, Y. Tomer, T.F. Davies
Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA
Thursday, November 8, 2001
Morning Session

10:00 - 11:30 am  Simultaneous Symposia

Regency Ballroom
Clinical: Thyroid Grand Rounds
Chair: Anthony S. Jennings
Speakers: E. Chester Ridgway
        Gregory A. Brent
        Douglas Ross
        David S. Cooper

Supported by an educational grant from Abbott Laboratories

Palladian Room
Basic: Autoimmunity and the Thyroid
Chair: Terry J. Smith

Models of Graves’ Disease Bellur S. Prabhakar
TSH Receptor as an Autoantigen Basil Rapoport
Thyroid Cell Apoptosis and Autoimmunity James R. Baker, Jr.

Panel Discussion

11:30 am - 12:30 pm  Meet the Professor Luncheons
Advance purchase required; admission by ticket only

Calvert Room
Breast Cancer and Thyroid Disease
Peter P. Smyth

Diplomat Room
Gene Expression Profiling and DNA Micro Array
Paul M. Yen

Executive Room
Cardiovascular Effects of Thyroid Hormone
Irwin L. Klein

Supported by an educational grant from Abbott Laboratories
Thursday, November 8, 2001
Morning and Afternoon Sessions

11:30 am Senate Room
12th International Thyroid Congress
International Coordinating Committee
Delegates’ Lunch Meeting
Asia Oceania Thyroid Association
Latin American Thyroid Society
European Thyroid Association
American Thyroid Association

12:45 - 2:15 pm Simultaneous Symposia

Regency Ballroom
Clinical: Thyroid Cancer
Chair: Steven I. Sherman
- PET Scanning R. Michael Tuttle
- rhTSH for Use in I-131 Therapy Paul W. Ladenson
- Management of Advanced/Aggressive Thyroid Cancer Matthew D. Ringel

Supported by Genzyme, Inc.

Palladian Room
Basic: T3 Receptor Isoform Specific Effects
Chair: Wolfgang H. Dillmann
- Structure of T3 Receptor alpha and T3 Receptor beta John D. Baxter
- T3R alpha Predominant Effects Wolfgang H. Dillmann
- T3R beta Predominant Effects Douglas Forrest
- T3R beta2 Effects in Pituitary Fredric E. Wondisford

Panel Discussion

2:15 - 3:15 pm Regency Ballroom
Van Meter Award Lecture – To Be Announced
Established in 1930, the Van Meter is awarded to an investigator younger than age 41 for outstanding contributions to research on the thyroid gland or related subjects.
Supported by an educational grant from Quest Diagnostics’ Nichols Institute
Thursday, November 8, 2001
Afternoon Session

3:15 - 3:45 pm  Ambassador and Regency Ballrooms
Exhibits, Poster Review, and Coffee Break

Regency Ballroom

Review of Posters:
Program Numbers 5 to 40 (Poster Plus)
Program Numbers 107 to 165
Investigators available to discuss their posters

3:45 - 4:45 pm  Regency Ballroom
Short Call Abstract Presentations
Chairs: William W. Chin and Michael M. Kaplan
A forum presenting the latest in thyroid-related research
(abstracts are in program insert)

Short Call Abstract 1  3:45 pm  Thyroid Hormone Metabolism
TYPE 2 IODOTHYRONINE DEIODINASE IS ESSENTIAL FOR ADAPTIVE THERMOGENESIS IN BROWN ADIPOSE TISSUE
A.C. Bianco1, L.A. Jesus1, S.D. Carvalho1, M.O. Ribeiro1, M. Schneider2, S.-W. Kim1, J.W. Harney1, P.R. Larsen3
1Thyroid Division, Brigham and Women's Hospital, Boston, Massachusetts, and 2Department of Physiology, Dartmouth Medical School, Lebanon, New Hampshire, USA

Short Call Abstract 2  4:00 pm  Cancer
BOTH NEAR-TOTAL/TOTAL THYROIDECTOMY (NTT) AND THYROID HORMONE SUPPRESSION THERAPY (THST) IMPROVE SURVIVAL OF PATIENTS WITH PAPILLARY THYROID CARCINOMA
J. Jonklaas, N. Sarlis, D. Litofsky, D. Cooper, K. Ain, S. Bigos, J. Brierley, B. Haugen, P. Kim, P. Ladenson, P. Marks, J. Robbins, D. Ross, M. Skarulis, H. Maxon, S. Sherman
National Thyroid Cancer Treatment Cooperative Study Group, Houston, Texas, USA

Short Call Abstract 3  4:15 pm  Cancer
SPOT 14 PROMOTES LIPID SYNTHESIS, GROWTH, AND ANTI-APOPTOSIS IN BREAST CANCER AND MAMMARY EPITHELIAL CELLS
O. Kulinets, C. McGraw, J. Kung, J. Moncur, W. Kinlaw
Department of Medicine, Division of Endocrinology, Dartmouth Medical School, Hanover, New Hampshire, USA

Short Call Abstract 4  4:30 pm  Cancer
OVEREXPRESSION OF A METASTASIS INHIBITING RECEPTOR (METASTIN RECEPTOR) IN PAPILLARY, BUT NOT FOLLICULAR, THYROID CARCINOMA
M.D. Ringel1, V. Bernet2, H. Burch2, F. Schuppert1, K.D. Burman1, M. Saji1
1Washington Hospital Center and MedStar Research Institute, Washington, DC; 2Walter Reed Army Medical Center, Washington, DC, USA; and 1Hospital Bad Oeyenhausen, Oeyenhausen, Federal Republic of Germany
Thursday, November 8, 2001
Afternoon Session and Evening

4:45 - 6:15 pm  Simultaneous Symposia

Diplomat Room

**Clinical: Developments in Nuclear Medicine**

Moderator: Howard J. Dworkin

- Treatment of Large Toxic and Non-toxic Goiters with I-131  John E. Freitas
- Octreotide Scanning in Graves’ Disease  George J. Kahaly
- Altered Response to I-131 After Antithyroid Drug Treatment of Hyperthyroidism  Henry B. Burch

Palladian Room

**Basic: Deiodinases and Thyroid Hormone Metabolism: Advances and Controversies**

Moderator: P. Reed Larsen

- Thyroid Hormone Deiodinases as Selenocysteine Proteins  Marla J. Berry
- Regulation of Deiodinase II  Antonio C. Bianco
- Animal Models of DII Null Mutation  Donald L. St. Germain

Panel Discussion

6:45 - 9:30 pm  Blue Room

**Abbott Night of Appreciation**

Admission by name badge
[this page is intentionally left blank so that Friday’s program can begin on an even-numbered page. this page is not to be printed. it’s included just as a reminder that a blank page goes here]
Special Program  
Friday, November 9, 2001

6:00 - Palladian Room  
7:45 am **Frontiers in the Clinical Applications of Recombinant TSH**  
Moderator: Paul W. Ladenson

- rTSH-Stimulated Thyroglobulin Testing  
  Leonard Wartofsky
- rTSH-Stimulated Radioiodine Ablation of Thyroid Remnants  
  Richard J. Robbins
- rTSH-Stimulated Radioiodine Therapy for Nodular Goiter  
  Geraldo Medeiros-Neto

*Sponsored by Montefiore Medical Center, The University Hospital for the Albert Einstein College of Medicine*  
*Credit issued by Albert Einstein College of Medicine*  
*Supported by an unrestricted educational grant from Genzyme, Inc.*
Friday, November 9, 2001

8:00 - 9:00 am  Regency Ballroom
Sidney H. Ingbar Distinguished Lectureship
This award recognizes outstanding academic achievements in thyroidology, in keeping with the innovation and vision that epitomized Dr. Ingbar’s brilliant investigative career. The award is conferred upon an established investigator who has made major contributions to thyroid-related research over many years. Supported by an educational grant from Abbott Laboratories

Metabolizing Thyroid Hormone: Where, When, and Why?
Valerie Anne Galton, Ph.D.
Professor of Physiology
Dartmouth Medical School
Lebanon, New Hampshire

9:00 - 10:00 am  Simultaneous Symposia

Regency Ballroom
Clinical: Outpatient Thyroid Surgery – Pros and Cons
Moderator: Quan-Yang Duh
Speakers: Paul LoGerfo
          Robert Udelsman
          Geoffrey B. Thompson

Palladian Room
Basic: Thyroid Cancer and Gene Rearrangement
Moderator: Bryan R. Haugen
          PAX8–PPARγ1 Fusion and Thyroid Cancer         Todd G. Kroll
          Medullary Cancer and RET Gene                  Robert F. Gagel
Supported by Genzyme, Inc.
Friday, November 9, 2001
Review of Posters 180 to 238 – Regency Ballroom

10:00 - 10:30 am Ambassador and Regency Ballrooms
Exhibits, Poster Review, and Coffee Break

Regency Ballroom
Review of Posters
Program Numbers 5 to 40 (Poster Plus)
Program Numbers 180 to 238
Investigators available to discuss their posters

Program Numbers 180 to 238:

180  Autoimmunity
HUMAN TSHR IMMUNIZATION INITIATES GRAVES' DISEASE IN CHINESE HAMSTERS
T. Ando, M. Imaizumi, A. Pritsker, T. Davies
Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA

181  Autoimmunity
AUTOIMMUNE THYROID DISEASE AND URINARY IODINE EXCRETION IN THE OLD ORDER AMISH
University of Maryland Medical System and Johns Hopkins Hospital, Baltimore, Maryland, USA

182  Autoimmunity
MORE ON THE ROLE OF HLA GENES IN THE SUSCEPTIBILITY TO AUTOIMMUNE THYROID DISEASE IN 102 FAMILIES
Y. Ban, Y. Tomer, E.S. Concepcion, D.A. Greenberg, T.F. Davies
Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine and Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA

Program Number 183 has been withdrawn

184  Autoimmunity
ETHNIC VARIATION IN AUTOIMMUNE THYROID DISEASE IN SRI LANKA
Department of Medicine, University of Wales College of Medicine, Cardiff, Wales, United Kingdom
185 Autoimmunity
AUTOIMMUNE THYROIDITIS AND THYROID CARCINOMA IN CHILDHOOD
A. Kurtev
University Pediatric Hospital, Sofia, Bulgaria

186 Autoimmunity
PAINFUL HASHIMOTO THYROIDITIS (HT) UNRESPONSIVE TO ANTI-INFLAMMATORY AGENTS: CASE REPORTS DOCUMENTING THE EFFECTIVENESS OF SURGERY
L. Gourgiotis1, N. Al-Zubaidi2, D.A. Papanicolaou2, L. Guthrie1, M.C. Skarulis1, M.J. Merino3, H.R. Alexander2, S.K. Libutti1, N.J. Sarlis1
1National Institute of Diabetes and Digestive and Kidney Diseases, 2National Institute of Child Health and Human Development, and 3National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

187 Cancer
IMMUNOHISTOCHEMICAL EXPRESSION OF RETINOID X RECEPTOR (RXR) ISOFORMS IN HUMAN THYROID TUMORS
Y. Takiyama, N. Miyokawa, A. Sugawara, S. Kato, K. Ito, K. Sato, M. Katagiri
Second Department of Pathology, Asahikawa Medical College, Hokkaido, Japan

188 Cancer
SODIUM IODIDE SYMPORTER (NIS) AND IODIDE IN THYROIDAL AND EXTRATHYROIDAL TISSUES
R. Dwyer, D. Smith, A. Hill, E. McDermott, N. O'Higgins, P. Smyth
University College Dublin and St. Vincent's University Hospital, Dublin, Ireland

189 Cancer
THE BENZOQUINONE ANSAMYCIN GELDANAMYCIN INDUCES CYTOTOXICITY AND INHIBITS TUMOR INVASION BY EPIDERMAL GROWTH FACTOR IN HUMAN THYROID CANCER CELL LINES
J. Park, M. Yeh, M. Wong, Q. Duh, O.H. Clark
Department of Surgery, University of California San Francisco/Mount Zion Medical Center, San Francisco, California, USA

190 Cancer
SODIUM IODIDE SYMPORTER MEDIATED TUMOR IMAGING AND RADIOIODINE THERAPY IN RATS BEARING INTRACEREBRAL GLIOMA
Departments of Physiology and Cell Biology, Pathology, Radiology, and Internal Medicine, Ohio State University, Columbus, Ohio, USA

191 Cancer
A RETROSPECTIVE COMPARISON OF THYROID REMNANT ABLATION RATES FOLLOWING HYPOTHYROID PREPARATION OR rhTSH PREPARATION IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA
Endocrinology, Nuclear Medicine, Head and Neck Surgery, Clinical Chemistry, and Pathology Services, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
INTER-INSTITUTIONAL REVIEW OF THYROID FNA: IMPACT ON CLINICAL MANAGEMENT OF THYROID NODULES
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA

THREE WEEK THYROXINE WITHDRAWAL-THYROGLOBULIN STIMULATION TEST TO DETECT RESIDUAL/RECURRENT DIFFERENTIATED THYROID CARCINOMA
Departments of Otolaryngology, Surgery, and Medicine, Mount Sinai Hospital and the University of Toronto School of Medicine, Toronto, Ontario, Canada

TSH-STIMULATED SERUM THYROGLOBULIN IN THE 1-10 NG/ML RANGE SUGGESTS A LOW LONG-TERM RECURRENCE RISK FOR PAPILLARY THYROID CANCER (PTC)
S. Fatemi1, J. Nicoloff2, J. LoPresti2, C. Spencer2
1Southern California Permanente Medical Group and 2Keck School of Medicine, University of Southern California, Los Angeles, California, USA

THE BELARUS-USA CHERNOBYL THYROID DISEASE COHORT STUDY (CTDCS): CORRELATION OF URINE IODINE CONCENTRATION WITH SERUM THYROGLOBULIN (TG) AND THYROID CANCER, NODULES, AND ULTRASOUND (US) VOLUME
V. Ostapenko1, O. Polyanskaya1, S. Petrenko1, L. Danilova1, V. Drozd1, E. Buglova1, N. Lesnikova1, V. Rzheutski1, D. Perevoznikov1, A. Tjuricov1, V. Stezhko1, A.B. Brill2, D. Fink2, E. Greenebaum2, I. Masnyk3, R.J. McConnell2, J. Robbins4
1Clinical Research Institute of Radiation Medicine and Endocrinology, Ministry of Health, Minsk, Belarus; 2Columbia University, New York, New York; and 3National Cancer Institute and 4National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Rockville, Maryland, USA

REGIONAL NECK FAILURE AFTER COMPREHENSIVE NODE DISSECTION FOR PAPILLARY THYROID CANCER IS UNIFORMLY FATAL
J.F. Pingpank, A.R. Sasson, A.P. Hanlon, T. LeVoyer, C. Freidman, J.A. Ridge
Head and Neck Surgery Section, Department of Surgical Oncology, and the Departments of Radiation Oncology and Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
Cancer

ACTIVATION OF Wnt SIGNALING IN DIFFERENTIATED HUMAN THYROID CANCERS
Nagasaki University School of Medicine, Nagasaki, Japan

Cancer

EPIDEMIOLOGICAL STUDY ON THE INCIDENCE OF THYROID DISEASES IN CHILDREN AROUND CHERNOBYL BORN BEFORE AND AFTER THE ACCIDENT
Atomic Bomb Disease Institute, Nagasaki University School of Medicine, Nagasaki, Japan

Cancer

THE USE OF CYTOKERATIN 19 mRNA EXPRESSION AS A MARKER FOR CIRCULATING TUMOR CELLS IN THYROID CANCER
R.M. Tuttle, S. Bhattacharya, R. Robbins, M. Ringel, R. Ghossein
Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Cancer

FREQUENCY OF Protooncogene RET MUTATIONS IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2) SYNDROMES
M. Puñales-Khaled, H. Graf, J. Gross, A.L. Maia
Division of Endocrinology, Hospital de Clinicas de Porto Alegre, UFRGS, Porto Alegre, Brazil

Cancer

PAPILLARY THYROID CARCINOMA OCCURS AS A FEATURE OF COWDEN DISEASE
Division of Endocrinology, Mayo Clinic and Foundation, Rochester, Minnesota, USA

Program Number 203 will be displayed on Wednesday, November 7 after Program Number 100

Cancer

IS BAG-1 A USEFUL MOLECULAR MARKER IN THE DIFFERENTIATION OF THYROID CANCER FROM BENIGN THYROID NODULES?
Y. Vaishnav, J. Anderson, C. Adair, B. Reinhardt, M. Saji, K. Burman, H. Burch, M. Ringel, V. Bernet
Endocrinology Service, Division of Clinical Investigation, and Pathology Service, Walter Reed Army Medical Center, and Endocrinology Service, Washington Hospital Center, Washington, DC, USA
205  Cancer  
**TUBULIN-BINDING AND ANTI-PROLIFERATIVE ACTIVITY OF THYROID HORMONE ANALOGUES**  
Karo Bio AB, Novum, Huddinge, Sweden

206  Cancer  
**HYPERCALCEMIA AND LEUKOCYTOSIS SECONDARY TO METASTATIC THYROID CANCER**  
Y. Ousman, M. Ringel, K. Burman  
Division of Endocrinology, Washington Hospital Center, Washington, DC, USA

Program Number 207 has been withdrawn

208  Cancer  
**UNFAVORABLE COURSE OF ONE CASE OF PAPILLARY THYROID MICROCARCINOMA**  
R. Antonelli, P. Daniele, M. Terlini  
Division of Endocrinology, S. Eugenio Hospital, Rome, Italy

209  Cell Biology  
**CELL CYCLE ARREST OF ANAPLASTIC THYROID CARCINOMA CELLS INDUCED BY BMP-7**  
A. Franzén, N-E. Heldin  
Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University Hospital, Uppsala, Sweden

210  Cell Biology  
**PROTEASOME ACTIVITY IN VARIOUS THYROID DISEASES AND REGULATION OF TRAIL-MEDIATED APOPTOSIS**  
H. Yamazaki¹, E. Mezosi¹, P.G. Gauger², N.W. Thompson², J.R. Baker, Jr.¹,³  
Departments of ¹Internal Medicine and ²Surgery, and ³Center for Biologic Nanotechnology, University of Michigan Medical Center, Ann Arbor, Michigan, USA

211  Cell Biology  
**GLYCOSAMINOGLYCANS IN THE THYROID**  
C. Antunes¹, E. Steffens¹, A. Viktor¹, G.J. Kahaly¹  
Departments of ¹Endocrinology and Metabolism and ³Medical Statistics, Gutenberg University Hospital, Mainz, Germany

212  Cell Biology  
**PPAR-(GAMMA) ANTAGONIST: POSSIBLE THERAPY FOR THYROID EYE DISEASE?**  
K.J. Starkey, J.S. Davies, M. Evans, M. Ludgate  
Department of Medicine (Endocrinology), UWCM, Cardiff, United Kingdom
THE PROTEIN KINASE C PATHWAY INHIBITS IODIDE UPTAKE VIA Na\textsuperscript{+}K\textsuperscript{+}ATPase IN CALF THYROID CELLS
L.V. Bocanera, L. Krawiec, G. Nocetti, G.J. Juvenal, D. Silberschmidt, M.A. Pisarev
Nuclear Biochemistry Division, Department of Radiobiology, CNEA, and Department of Biochemistry, University of Buenos Aires School of Medicine, Buenos Aires, Argentina

LONG-TERM FOLLOW-UP OF BENIGN NODULAR THYROID PATHOLOGY BY REPEAT FINE NEEDLE ASPIRATION
A. Orlandi, A. Puscar, E. Capriata, E. Marx, H. Fideleff
Endocrinology Unit, Pathology Division, Hospital Alvarez, Buenos Aires, Argentina

Program Number 215 has been withdrawn

COMPARISON OF THE PERIPHERAL EFFECTS OF SUPPRESSIVE TSH SECRETION DOSES OF 3,5,3\textsuperscript{'}-TRIODO THYROACETIC ACID AND LEVOTHYROXINE
G. Brenta, M. Schnitman, O. Fretes, M. Gurfinkel, S. Damilano, M.A. Pisarev
Department of Endocrinology and Metabolism, Hospital Francés de Buenos Aires, Argentina

EFFECTS OF CHRONIC IODINE EXCESS IN PEACE CORPS VOLUNTEERS
E.N. Pearce\textsuperscript{1}, A.R. Gerber\textsuperscript{2}, D.B. Gootnick\textsuperscript{2}, L.K. Khan\textsuperscript{3}, R. Li\textsuperscript{3}, S. Pino\textsuperscript{1}, L.E. Braverman\textsuperscript{1}
\textsuperscript{1}Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts; \textsuperscript{2}Peace Corps Office of Medical Services, Washington, DC; and \textsuperscript{3}CDC-NCCDPHP, Atlanta, Georgia, USA

MOLECULAR CHARACTERISATION OF CONGENITAL HYPOTHYROIDISM
N. Jordan\textsuperscript{1,2}, J. Gregory\textsuperscript{3}, S. Keeling\textsuperscript{4}, C. Evans\textsuperscript{5}, M. Ludgate\textsuperscript{2}
Departments of \textsuperscript{1}Medicine, \textsuperscript{2}Medical Biochemistry, \textsuperscript{3}Child Health, and \textsuperscript{4}Medical Genetics, UWCM, Cardiff, Wales, United Kingdom

RESISTANCE TO THYROID HORMONE DOES NOT ABROGATE THE TRANSIENT THYROTOXICOSIS ASSOCIATED WITH GESTATION
J. Anselmo, T. Kay, K. Dennis, R. Szumulewitz, S. Refetoff, R. Weiss
Hospital Divino Espirito Santo, Ponta Delgada, Azores, Portugal, and Department of Medicine, University of Chicago, Chicago, Illinois, USA
220  Clinical
THE EFFECT OF THEOPHYLLINE ON RADIOIODINE UPTAKE BY THE HUMAN THYROID
R. Zemans, P.W. Ladenson
Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

221  Clinical
RESISTANCE TO THYROID HORMONE (RTH) IN A PATIENT WITH NORMAL THYROID HORMONE (TH) RECEPTORS ALPHA AND BETA
S. Parikh, S. Ando, A. Schneider, M.C. Skarulis, N.J. Sarlis, P.M. Yen
Clinical Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, and National Institute on Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA

222  Clinical
THYROID AUTOIMMUNE DISEASE IN HEPATITIS C AND B INFECTED PATIENTS
L. Figueroa¹, E. Jimenez¹, A. Montilla¹, L. Deibis²
¹Endocrinology and Metabolism Service, Caracas University Hospital, and ²Immunology Institute, Universidad Central de Venezuela, Venezuela

223  Clinical
THYROID SIZE DETERMINATION BY TRADITIONAL PALPATION METHOD POINTS TO "NO GOITER" ENDEMIA WHEREAS ULTRASONOGRAPHY CONSISTENTLY IDENTIFIES GOITER IN WELL-NOURISHED IODINE REPLETE ADULTS: POSSIBLE ROLE OF FLAVONOIDs
S. Brahmbhatt, R. Brahmbhatt, C. Eastman, S. Boyages
Department of Diabetes and Endocrinology and Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW 2145, Australia

224  Clinical
PREDICTABILITY OF BODY CELL MASS BY BIOIMPEDANCE IN THYROTOXICOSIS: COMPARISON WITH WHOLE-BODY K40 COUNTING
M. Dittmar¹, H. Reber², G.J. Kahaly³
Departments of ¹Biology/Anthropology, ²Nuclear Medicine, and ³Endocrinology/Metabolism, Gutenberg University, Mainz, Germany

225  Clinical
INTERLEUKIN-6 AND THYROID HORMONE IN THE PEDIATRIC CARDIAC SURGERY PATIENT
C.K. McMahon, V.A. Parnell, I. Klein, K. Ojamaa
North Shore University Hospital/New York University School of Medicine, Manhasset, New York, USA

226  Clinical
THYROID FINDINGS IN ASYMPTOMATIC ADULTS IN VENEZUELA: A CLINICAL, LABORATORY, AND ULTRASONOGRAPHIC STUDY
L. Figueroa, R.M. Baldonado, C.A. Palermo
Endocrinology and Metabolism Service, Caracas University Hospital, Universidad Central de Venezuela, Venezuela
227  Clinical
TWO SIBLINGS WITH SUBACUTE THYROIDITIS
H. Fukazawa, H. Kurihara, J. Sasaki, K. Tanimura
Morioka National Hospital, Morioka, Japan

228  Clinical
A PARATHYROID CYST IN THE THYROID GLAND
H. Kurihara, S. Tanimura, J. Sasaki
Kurihara Thyroid Clinic, Morioka, Iwate, Japan

229  Thyroid Hormone Action
OXIDATION OF LDL IN OVERT AND SUBCLINICAL HYPOTHYROIDISM
L.H. Duntas, E. Mantzou, M. Kalarritou, D.A. Koutras
Evgenidion Hospital, University of Athens, Athens, Greece

230  Thyroid Hormone Action
GLOBAL ANALYSIS OF THYROID HORMONE-RESPONSIVE GENES IN RAT
PITUITARY GC CELLS BY THE SERIAL ANALYSIS OF GENE EXPRESSION
S.W. Kim, S.I. Kim, P.R. Larsen
Thyroid Division, Brigham and Women's Hospital, Harvard Medical School, Boston,
Massachusetts, USA

231  Thyroid Hormone Action
COMPARATIVE EFFECTS OF THE SELECTIVE THYROID HORMONE RECEPTOR
(TR-BETA1) AGONIST KB-000,141 (KB) ON CHOLESTEROL, METABOLIC RATE
AND HEART RATE IN RATS
G. Grover1, J. Baxter2, L. Ye3, L-Y. Lin3, J. Malm3, L-G. Bladh3, P. Sleph3, R. George1,
K. Mellstrom3
1Bristol-Myers Squibb, Pennington, New Jersey; 2University of California San Francisco, San
Francisco, California, USA; and 3Karo BIO AG, Sweden

232  Thyroid Hormone Action
INFLUENCE OF THYROID HORMONES ON NEURONAL DIFFERENTIATION
D. Laverdure Dupont, D. Bellabarba
Endocrine Division and Department of Physiology, Medical School, University of Sherbrooke,
Sherbrooke, Quebec, Canada

233  Thyroid Hormone Action
CRYSTAL STRUCTURE ANALYSIS OF TETRAIODOTHYROACETIC ACID (T4Ac)
BOUND TO HUMAN AND RAT TRANSTHYRETIN
V. Cody, J.R. Luft, W. Pangborn, A. Wojtczak, T. Muziol
Hauptman-Woodward Medical Research, Buffalo, New York, USA, and N. Copernicus
University, Torun, Poland

Program Number 234 has been withdrawn.
235  Thyroid Hormone Metabolism
TELEOST LIVER EXPRESSES DEIODINASE TYPE 1 mRNA
A. Orozco, P. Villalobos, C. Valverde
Centro de Neurobiología, UNAM, Campus UNAM-UAQ-Juriquilla, Querétaro, México

Program Number 236 has been withdrawn

237  Thyroid Hormone Metabolism
ACTIVITY AND RESPONSE TO SERUM OF THE MOUSE AND HUMAN TYPE 3 DEIODINASE GENE (DIO3) PROMOTERS
A. Hernandez, D.L. St. Germain
Dartmouth Medical School, Lebanon, New Hampshire, USA

238  Thyroid Hormone Metabolism
DEXAMETHASONE INHIBITS GROWTH FACTOR-INDUCED TYPE 3 DEIODINASE (D3) ACTIVITY AND mRNA EXPRESSION IN A CULTURED CELL LINE DERIVED FROM RAT NEONATAL BROWN FAT VASCULAR-STROMAL (BVS-1) CELLS
A. Hernandez, D.L. St. Germain
Dartmouth Medical School, Lebanon, New Hampshire, USA
10:30 - 11:30 am  Regency Ballroom

**Plenary Session – Topic Highlights**

**Oral Abstract Presentations**

Chair: Frances E. Carr

166 10:30 am  Thyroid Hormone Action

**SERINE 142 OF THE NUCLEAR THYROID HORMONE RECEPTOR (BETA)1 IS A MITOGEN-ACTIVATED PROTEIN KINASE TARGET IN CV-1 CELLS TREATED WITH L-THYROXINE**

H.-Y. Lin, F.B. Davis, B.L. West, P.J. Davis

Clinical Research Institute, Albany Medical College, Wadsworth Center, New York State Department of Health, and Stratton VA Medical Center, Albany, NY; and Department of Biochemistry, University of California at San Francisco, San Francisco, California, USA

167 10:45 am  Thyroid Hormone Action

**THYROID FUNCTION IN MICE DEFICIENT IN THYROID HORMONE RECEPTOR α OR β IN COMBINATION WITH SRC-1: EVIDENCE FOR ISOTYPE SPECIFICITY**

P. Sadow1, O. Chassande2, J. Xu3, E. Koo3, J. Samarut3, B. O’Malley3, S. Refetoff1, R. Weiss1

1Department of Medicine, University of Chicago, Chicago, Illinois, USA; 2Ecole Normale Superieure, Lyon, France; and 3Baylor College of Medicine, Houston, Texas, USA

Program Number 168 has been withdrawn

Program Number 169 will be presented at 3:30 pm today as part of the session on “Thyroid Hormone Metabolism and Action”

170 11:00 am  TRH-TSH

**CELL SURFACE-ANCHORED EXTRACELLULAR DOMAIN OF THE TSH RECEPTOR MODULATES EXPRESSION AS WELL AS BASAL AND TSH-DEPENDENT ACTIVATION**

V. Fremont, K.P.T. Tong, B.D. Weintraub, M.W. Szuklinski

University of Maryland, Baltimore, Maryland, and Trophogen, Inc., Rockville, Maryland, USA

171 11:15 am  TRH-TSH

**STIMULATORY AND INHIBITORY EFFECTS OF TTF-2 ON GLYCOPROTEIN HORMONE (ALPHA)-SUBUNIT PROMOTER ACTIVITY IN PITUITARY AND NON-PITUITARY CELL LINES**

V. Sarapura, D. Haakinson

Division of Endocrinology, Metabolism and Diabetes, University of Colorado Health Sciences Center, Denver, Colorado, USA
Friday, November 9, 2001
Morning and Afternoon Sessions

11:45 am - Ambassador and Regency Ballrooms
12:45 pm Lunch, Exhibits, and Poster Review
(12:30 Dessert in the Regency Ballroom and Palladian Room)
Lunch supported by Abbott Laboratories
Program Numbers 5 to 40 (Poster Plus)
Program Numbers 180 to 238
Investigators available to discuss their posters

12:45 - 2:00 pm Simultaneous Symposia
Regency Ballroom
Clinical: Clinical Research in Thyroidology:
Journal Editors’ Perspectives
Moderator: Michael M. Kaplan
Panelists: Terry F. Davies
Delbert A. Fisher
Jerome M. Hershman
Robert D. Utiger
Supported by an educational grant from Abbott Laboratories

Palladian Room
Basic: Protein Trafficking in the Thyrocyte
Chair: Leonard D. Kohn
Lipoprotein Receptors (Megalin) and Thyroglobulin Uptake
Michel Marino
Thyroglobulin Trafficking in the Thyrocyte
Paul S. Kim
Thyroglobulin Signaling: Role of the ASGPR in Thyroid and Nonthyroid Tissues
Leonard D. Kohn

2:00 - 3:00 pm Palladian Room
Paul Starr Award Lecture
This annual Award recognizes an outstanding contributor to clinical thyroidology. The Award is supported in part by generous contributions from Boris Catz, M.D., and from Monarch Pharmaceuticals.

Graves’ Ophthalmopathy: A Personal Odyssey
Colum A. Gorman, M.B., B.Ch., Ph.D.
Professor of Medicine, Mayo Foundation
Interim Chair, Department of Health Sciences Research
Mayo Clinic, Rochester, Minnesota
Friday, November 9, 2001
Afternoon Session

3:00 - 3:15 pm  Palladian Room
Coffee Break

3:15 - 4:00 pm  Simultaneous Sessions

Regency Ballroom
Thyroid and the Brain
Oral Abstract Presentations
Chairs: Alan P. Farwell and William B. Kinlaw III

172  3:15 pm  Thyroid and the Brain
BRAIN GLUCOSE UTILIZATION IN MICE WITH A TARGETED MUTATION IN
THE THYROID HORMONE α OR β RECEPTOR GENE
Y. Itoh¹, T. Esaki¹, M. Kaneshige², H. Suzuki², L. Sokoloff¹, S.-y. Cheng², J. Nunez¹
¹Laboratory of Cerebral Metabolism, National Institute of Mental Health, and ²Laboratory of
Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland,
USA

173  3:30 pm  Thyroid and the Brain
THYROID HORMONE REGULATES THE ACCUMULATION OF
OLIGODENDROCYTES IN THE DEVELOPING RAT BRAIN
M.M. Seibel, S.A. Jones, C.N. Mariash, G.W. Anderson
University of Minnesota, Minneapolis, Minnesota, USA

174  3:45 pm  Thyroid and the Brain
SELECTIVE MEMORY DISTURBANCES IN CHILDREN WITH CONGENITAL
HYPOTHYROIDISM SIGNIFY THAT THYROID HORMONE IS NECESSARY FOR
HUMAN HIPPOCAMPAL FORMATION
J. Rovet, D. Jewell, S. Hepworth
University of Toronto and Hospital for Sick Children, Toronto, Ontario, Canada

Program Number 175 has been withdrawn
3:15 - 4:00 pm Simultaneous Sessions

**Palladian Room**

**Thyroid Hormone Metabolism and Action**

Oral Abstract Presentations

Chairs: Donald L. St. Germain and Rebecca S. Bahn

176 3:15 pm  Thyroid Hormone Metabolism

**DIFFERENTIAL REGULATION OF TYPE 1 AND TYPE 3 DEIODINASE ACTIVITY IN VENTRICULAR TISSUE DURING PATHOLOGICAL HYPERTROPHY**

A. Schiel, W. Simonides, C. van Hardeveld, F. Wassen, G. Kuiper, T. Visser, B. Zandieh-Doulabi, O. Bakker, W. Wiersinga

Institute for Cardiovascular Research, Vrije Universiteit Medical Center, Amsterdam; Department of Internal Medicine III, Erasmus University, Rotterdam; and Department of Endocrinology, Amsterdam Medical Center, Amsterdam, The Netherlands

Program Numbers 177 and 178 have been withdrawn

169 3:30 pm  Thyroid Hormone Action

**LACK OF SRC-1 INCREASES RESISTANCE TO THYROID HORMONE IN MICE WITH A TARGETED MUTATION IN THE THYROID HORMONE RECEPTOR β GENE**

Y. Kamiya¹, M. Kaneshige¹, J. Xu², M. Willingham³, B. O’Malley³, S-y. Cheng¹

¹Laboratory of Molecular Biology, National Cancer Institute, Bethesda, Maryland; ²Department of Cell Biology, Baylor College of Medicine, Houston, Texas; and ³Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA

179 3:45 pm  Thyroid Hormone Metabolism

**FUNCTIONAL CHARACTERIZATION OF PENDRIN AND TWO NATURALLY OCCURRING MUTANTS: EVIDENCE FOR PENDRIN-MEDIATED IODIDE EFFLUX**


Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University, Chicago, Illinois
Friday, November 9, 2001
Afternoon Session and Evening

4:00 - 4:45 pm  Palladian Room
National Academy of Clinical Biochemistry International
Thyroid Guidelines Development Workshop:
Implications for Clinical Practice
Carole A. Spencer
*Supported by an educational grant from Abbott Laboratories*

4:45 - 6:45 pm  Palladian Room
American Thyroid Association Annual Business Meeting
*ATA Members Only*

7:30 - 8:15 pm  Birdcage
ATA Annual Reception

8:15 - 11:00 pm  Empire Ballroom
ATA Annual Banquet
Advance purchase required; admission by ticket only
Music by Joe DiStefano

Historical Vignette
Medullary Carcinoma of the Thyroid and Calcitonin:
A Brief History
Clark T. Sawin
Special Program
Saturday, November 10, 2001

6:00 - Palladian Room
7:45 am  Sunrise “Early Riser” Seminar:
Hot Topics in Thyroidology
Chair: E. Chester Ridgway

Improving Outcomes in Thyroid Cancer
with TSH-Suppressive Therapy  Steven I. Sherman

Does Subclinical Hypothyroidism
Really Increase the Risk of
Cardiovascular Disease?  Leonard Wartofsky

Improving the Utility of Fine Needle
Aspiration Biopsy for the Diagnosis
of Thyroid Tumors  Bryan R. Haugen

Sponsored by The Endocrine Society
Supported by an unrestricted educational grant from Abbott Laboratories
8:00 - 9:00 am Simultaneous Sessions

Palladian Room
Clinical: Cancer
Oral Abstract Presentations
Chairs: Ian D. Hay and Quan-Yang Duh

251 8:00 am Cancer
SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS ARE ELEVATED IN METASTATIC DIFFERENTIATED THYROID CANCER BUT NOT INCREASED BY TSH STIMULATION
R.M. Tuttle, M. Fleisher, G.L. Francis, R.J. Robbins
Endocrinology Service, Department of Medicine, Clinical Chemistry Service, Department of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center, New York, New York, and Endocrinology Service, Department of Pediatrics, Walter Reed Army Medical Center, Washington, DC, USA

252 8:15 am Cancer
IS THE SERUM THYROGLOBULIN RESPONSE TO rhTSH SUFFICIENT BY ITSELF TO MONITOR FOR RESIDUAL DIFFERENTIATED THYROID CARCINOMA?
Endocrinology, Nuclear Medicine, and Clinical Chemistry Services, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

253 8:30 am Cancer
UTILITY OF ULTRASONOGRAPHY IN POST-SURGICAL MANAGEMENT OF PATIENTS WITH THYROID CARCINOMA
P. Arora, M. Blum
Division of Endocrinology, New York University Medical Center, New York, New York, USA

254 8:45 am Cancer
LACK OF IMPACT OF RADIOIODINE THERAPY IN THYROGLOBULIN-POSITIVE DIAGNOSTIC SCAN-NEGATIVE PATIENTS WITH FOLLICULAR CELL-DERIVED THYROID CANCER
V. Fatourechi, I. Hay, H. Javedan, G. Wiseman, B. Mullan, C. Gorman
Division of Endocrinology and Metabolism and Division of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota, USA
Saturday, November 10, 2001
Morning Session

8:00 - 9:00 am Simultaneous Sessions

Diplomat Ballroom
Basic: Thyroid Hormone Action, Thyroid and the Brain, and Cell Biology
Oral Abstract Presentations
Chair: Paul M. Yen

255 8:00 am Thyroid Hormone Action
THE EFFECTS OF T3 AND TRIAC ON HYPERTENSIVE CARDIOMYOPATHY IN DAHL RATS
P. Cettour¹, J.F. Aubert², P. Trigo Trindade¹, F. Pernin¹, R. Lerch¹, T. Visser³, H.R. Brunner², F. Rohner-Jeanrenaud¹, A. Burger¹
¹University of Geneva, Hopital Cantonal Universitaire, Geneva, Switzerland; ²Division of Hypertension, CHUV, Lausanne, Switzerland; and ³Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands

Program Number 256 has been withdrawn

242 8:15 am Cell Biology
EXAMINING THE TARGETING OF cog-MUTANT THYROGLOBULIN: ENDOPLASMIC RETICULUM RETENTION AND ASSOCIATED DEGRADATION
Y. Park, P. Arvan
Division of Endocrinology, Albert Einstein College of Medicine, Bronx, New York, USA

257 8:30 am Thyroid and the Brain
TESTING THE “ENDOCRINE DISRUPTOR” HYPOTHESIS FOR CHILDHOOD NEUROBEHAVIORAL DISORDERS
S.H. Lamm, O.P. Soldin, J.S. Lamm, S. Mosee, S.H. Lai
Consultants in Epidemiology and Occupational Health, Inc., Howard University School of Medicine, Washington, DC, and Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland, USA

Program Number 258 has been withdrawn

244 8:45 am Cell Biology
MOLECULAR ANALYSIS AND STRUCTURE/FUNCTION IMPLICATIONS OF TWO CONGENITAL NIS MUTATIONS (G93R and G395R)
O. Dohán, M. Paroder, V. Gavrielides, C. Ginter, M. Amzel, N. Carrasco
Albert Einstein College of Medicine, Bronx, New York, USA
Saturday, November 10, 2001
Morning Session

9:00 - 10:00 am Palladian Room
Abbott Laboratories State of the Art Lecture
Using Genomics to Understand Hormone Action
Paul Meltzer, M.D., Ph.D.
Head, Section of Molecular Genetics, Cancer Genetics Branch
National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Supported by an educational grant from Abbott Laboratories

10:00 - 10:15 am Palladian Room
Coffee Break

10:15 - 11:15 am Simultaneous Sessions
Palladian Room
Clinical Advances
Oral Abstract Presentations
Chairs: Kenneth D. Burman and Kenneth H. Hupart

245 10:15 am Clinical
ADMINISTRATION OF A SINGLE DOSE OF RECOMBINANT HUMAN THYROTROPIN ENHANCES THE EFFICACY OF THE RADIOIODINE (RAI) TREATMENT OF MULTINODULAR GOITER (MNG)
M. Silva, I. Rubió, C. Buchpiguel, R. Romão, S. Cardia, R. Camargo, E. Tomimori, E. Gebrin, G. Medeiros-Neto
Division of Endocrinology and Department of Radiology, University of São Paulo Medical School, São Paulo, SP, Brazil

246 10:30 am Clinical
LONG-TERM SAFETY OF ORBITAL RADIOTHERAPY FOR GRAVES' OPHTHALMOPATHY
C. Marcocci, L. Bartalena, G. Barbésino, R. Rocchi, M. Nardi, S. Mazzeo, F. Cartei, B. Mazzi, F. Menconi, A. Pinchera
Departments of Endocrinology and Metabolism, Neurosciences, and Oncology, University of Pisa, Pisa, and Department of Clinical and Biological Sciences, University of Insubria, Varese, Italy

Program Number 247 has been withdrawn

248 10:45 am Clinical
EXPERIENCE WITH ULTRASOUND-GUIDED FINE-NEEDLE ASPIRATION BIOPSY IN THE EVALUATION OF THYROID
F. Fierro-Renoy, R. Fierro-Benitez, R. Guerrero
Endocrinology Section, Hospital Metropolitano, Quito, Ecuador
Saturday, November 10, 2001
Morning Session

Program Number 249 is now an oral abstract presentation taking the place of Program Number 1

250  11:00 am   Clinical
DERMOPATHY OF GRAVES’ DISEASE (PRETIBIAL MYXEDEMA): LONG TERM OUTCOME
K. Schwartz, V. Fatourechi, D. Ahmed, G. Pond
Division of Endocrinology, Department of Dermatology and Section of Biostatistics, Mayo Clinic, Rochester, Minnesota, USA

10:15 - 11:15 am Simultaneous Sessions

Diplomat Room
Basic: Cell Biology
Oral Abstract Presentations
Chair: Terry J. Smith

239  10:15 am   Cell Biology
THE ROLE OF GRP94 IN THE PROCESSING OF THYROGLOBULIN MOLECULES BY FLUORESCENCE RESONANCE ENERGY TRANSFER SPECTRO-MICROSCOPY
S. Menon, J. Kim, W. Abplanalp, B. Li, P. Kim
Division of Endocrinology, University of Cincinnati, Cincinnati, Ohio, USA

240  10:30 am   Cell Biology
THERE IS AN INTRINSIC ULTRADIAN HORMONAL SECRETORY RHYTHM IN GH4C1 CELLS, WHICH IS REGULATED BY A POST-GOLGI MECHANISM INDEPENDENT OF TRANSLATION
M.A. Greer, S.E. Greer
Division of Endocrinology, Department of Medicine, Oregon Health Sciences University, Portland, Oregon

241  10:45 am   Cell Biology
ABERRANT APOPTOSIS IN THYROID CELLS FROM NODULAR GOITERS
E. Mezosi¹, J.D. Bretz¹, H. Yamazaki¹, S.H. Wang¹, P.G. Gauger², N.W. Thompson², J.R. Baker, Jr.¹,³
Departments of ¹Medicine and ²Surgery, and ³Center for Biologic Nanotechnology, University of Michigan Medical Center, Ann Arbor, Michigan, USA

Program Number 242 is being presented at 8:15 as part of the Basic Science session

243  11:00 am   Cell Biology
PRODUCTION OF POLYCLONAL ANTIBODY TO HUMAN TTF2 SUITABLE FOR IMMUNOCYTOCHEMISTRY
M.J. Sequeira¹,², F. Al-Khafaji¹, M.D. Lewis¹, M. Wheeler², B. Jasani¹, M. Ludgate¹
Departments of ¹Medicine/Endocrinology, ²Surgery, and ³Pathology, UWCM, Cardiff, Wales, UK

Program Number 244 is being presented at 8:45 as part of the Basic Science session
11:15 -12:45 pm Simultaneous Symposia

Palladian Room
Clinical: Thyroid Ultrasound
Moderator: Manfred Blum

- The Use of Ultrasound in Nodular Thyroid Disease: Susan J. Mandel
- Use of Ultrasound to Detect and Ablate Involved Nodes After Surgery: Carl C. Reading
- ATA and ETA Survey: Nontoxic Multinodular Goiter: Paul W. Ladenson

Diplomat Ballroom
Basic: Iodine Transport
Moderator: Sheue-yann Cheng

- Pendrin and Its Role in Thyrocytes, Inner Ear, and Kidney: Peter A. Kopp
- The Thyroidal Iodide Transporter as Potential Therapeutic Support for Prostate Cancer: John C. Morris, III
- Sodium Iodide Symporter (NIS): Structure/Function Relations and Pathophysiological Relevance: Nancy Carrasco

12:45 pm 73rd Annual Meeting Ends

Attendees may pick up their Continuing Medical Education certificate outside the Palladian Room as they leave the Meeting